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Aims and outline of this thesis 23
Studies in cluded in the thesis
In search of epidemiological risk factors for Chlamydia trachomatis (CT) and prevention of tubal pathology 
we performed two prospective-cohort studies. The results are presented in this thesis. The fi rst study 
describes the epidemiological data of patients with CT infections using a well defi ned cohort of patients 
visiting an outpatient department of Obstetrics and Gynaecology located in the central urban area of The 
Hague, and was reported in 2002-2004. To assess the value of different serological assays for the detection 
of CT antibodies a comparison is made in the same cohort. An evaluation of a new assay detecting heat 
shock protein 60 (HSP60) antibodies and its role in predicting tubal pathology has been made as well.
In 2007 a second, sequential study was started at the same outpatient department of Obstetrics and 
Gynaecology and the nearby regional sexually transmitted disease clinic to fi nalise some of the aims of 
the study, which will be outlined at the end of this chapter.
The time gap between the fi rst and second study has no consequences for the character of the study as 
a whole. Findings and conclusions of the fi rst part are still relevant and actual. The second part is a logical 







consequence of the fi rst, within the same subject of research, although some epidemiological data are 
continuously changing over time. 
Introduc tion to the thesis
CT infection is the most prevalent sexual transmitted disease in the Netherlands and worldwide. In the 
Netherlands approximately 60.000 people are infected each year of which 35.000 are women. In women 
approximately 70% of the infections are asymptomatic. However, infections caused by CT may lead to 
serious complications such as pelvic infl ammatory disease (PID). Functional damage to the tubes may 
result in (tubal factor) subfertility and ectopic pregnancy. Infections in pregnant women may lead to 
neonatal conjunctivitis and pneumonia. The highest prevalence is found in young sexually active women, 
who are especially at risk for complications. It is unknown why some women have asymptomatic infec-
tions and why others develop symptomatic upper genital tract infections. It has been suggested that 
different serovars and/or host-factors may be involved in the clinical course of infection, the rate of upper 
genital tract progression, and clearance or persistence of infection. 
Treatment is simple and effective. Late complications can be prevented if treatment is given in time. 
With the development of techniques to detect CT in urine samples screening programs have become 
reality and large scale screening programs for asymptomatic infections have been implemented.
In the population of obstetrical and gynaecological patients it is important to determine risk factors 
for infection. Uterine instrumentation such as intrauterine device (IUD) insertions and abortion curet-
tage may cause upper genital tract infection if an asymptomatic cervical infection is present, by ascending 
infection or by reactivation of viable microorganisms in the upper genital tract. 
To optimise prevention strategies for complications we wanted to determine host risk factors for CT 
infections for obstetrical and gynaecological patients. The dynamics of CT serovars need further evalua-
tion. Insight in changes of serovar distribution in different ethnic groups over time, in relation to clinical 
data, could contribute to understanding changes in the epidemiology of CT infections and have clinical 
implications. 
Classifi  cation
The genus Chlamydia consists of different species. Most well known are CT, Chlamydia psittaci, and 
Chlamydia pneumoniae (CP). Chlamydiae are associated with a broad spectrum of diseases, such as cardio-
vascular, pulmonary, and ocular disease, and urogenital tract infections1-3.
CT infects mainly human and is divided into two biovars (table 1). The trachoma biovar consists of 
serovar A-C, causing trachoma, and the serovars D-K, which infect the urogenital tract. The LGV biovar, 
consisting of serovars L1-L3, causes lymphogranuloma venereum. 
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Table 1. Human Chlamydia trachomatis serovar classifi cation and site of infl ammation
Chlamydia trachomatis
Biovar Serovar Host Site of infl ammation
Trachoma A, B, Ba, C Human Conjunctivae
Urogenital tract (rare)
D, Da, E, F, G, Ga, H, I, Ia, J, K Human Urogenital tract
Conjunctivae
Respiratory tract (rare)




Chlamydiae are nonmotile, gram-negative, obligate intracellular bacteria with a unique developmental life 
cycle (fi gure 1)4. 
Figure 1. Developmental cycle of Chlamydia trachomatis. (©Thesis T. Huittinen 2003)
The extracellular elementary body (EB) is the infectious, but metabolically inactive form, which is taken 
up by the host cell by inclusion. The EB transforms into the larger, non-infectious, metabolically active 
reticulate body (RB), which replicates by binary fi ssion (a process which results in the reproduction of 
a living prokaryotic cell by DNA replication and division into two parts which each have the potential to 
grow to the size of the original cell). Within 40-48 hours the RBs differentiate back to EBs, which are 







released from the inclusion vacuole by exocystosis or host cell lysis to infect other cells. The complete 
cycle from entry to release takes about 48-72 hours5,6. Chlamydiae have both RNA and DNA. The cell wall 
contains both proteins and lipids. The most prominent protein is the major outer membrane protein 
(MOMP). It has a function in maintaining the structural integrity of the cell wall and forms with Omp2 and 
Omp3 (cystine rich proteins located on the inner surface of the outer membrane) a disulfi de cross-linked 
complex in the cell wall7. This transmembrane protein with surface antigenic components can be used to 
identify the different CT serovars. Lipopolysaccharide (LPS) is a genus-specifi c antigen which is located 
on the surface of the MOMP.
Pathoge nesis
Although progress has been made in the past years, it is yet unknown why some women have asymp-
tomatic infections and why others develop symptomatic upper genital tract infections. It is also unclear 
why in some women the upper genital tract infection causes serious damage to the fallopian tubes, while 
in other women the infection is cleared, apparently without clinical consequences. Differences in the 
clinical course of the infection could be due to interaction between bacterial (virulence factors among 
different serovars, see serotyping), environmental (vaginal fl ora composition, co-infections) and host 
factors (genetic differences).
The susceptibility for a CT infection is, among other factors, infl uenced by the vaginal fl ora. The pres-
ence of co-infections, i.e. Neisseria gonorrhoeae (NG) or Candida albicans, may cause similar or dissimilar 
symptoms. An association with persistence of human papillomavirus (HPV) in the presence of a CT 
infection was found8. 
The host immune response plays an important role in the infl ammation and pathological tissue 
scarring in chlamydial disease. It has been proposed that women with weak cell-mediated immune 
responses to CT and strong antibody responses to CT are those susceptible to reinfection, slow to resolve 
infection and have high levels of clinical infl ammation (tissue scarring). Likewise, women with strong 
cell-mediated immune responses and comparatively low antibody responses are resistant to infection 
and less susceptible to disease9.
The humoral immune response is represented by the presence of antibodies. Especially chlamydial 
60 kDa heat shock protein (HSP60) is a predictor of upper genital tract infection10. Specifi c cytotoxic T 
cells are representations of the cellular immune response. These cells cause lysis of the CT infected cells 
through binding to CT antigens like MOMP, LPS and HSP6011,12.
Therefore, it is proposed that chronic infl ammation by repeated or persistent CT infection may lead to 
tissue scarring by release of cytokines or a continuous production of HSP60, which triggers the immune 
system leading to tissue damage13. Also the infl ammation caused by the activation of cytotoxic T cells, to 
eliminate CT infected cells, by HSP60 leads to scarring.
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Prevale nce and risk factors
The prevalence of CT infections depends on the population tested. Wilson et al. found prevalences rang-
ing from 1.7-17% in asymptomatic women in Europe14. Among young women attending STD clinics rates 
are well above 10%15, and in population-based studies among women under 30 year of age the prevalence 
was between 2-6% in the Netherlands16, Denmark17 and the United Kingdom18. In the literature several 
risk factors for CT infections have been identifi ed, such as young age, being of black race, recent new 
partner (< one year), number of sexual partners, condom use and complaints of postcoital bleeding in 
women19-21. In the Netherlands several similar risk factors have been identifi ed, including Surinam or 
Netherlands Antilles ethnicity22. Higher prevalences are found in urban areas16. However, it is unclear 
whether the same risk factors apply for an obstetrical and gynaecological population. 
Clinical co urse of infection
Women
Nearly 70% of the CT infections in women are asymptomatic and will therefore not be treated with antibi-
otics23. These women may play an important role in the transmission of infections with the risk of long-
term sequelae. Clinical manifestations of symptomatic infections include cervicitis, urethritis, endome-
tritis and PID. Most common complaints related to CT infections are abnormal vaginal discharge, dysuria 
and postcoital bleeding. In case of PID, pelvic-, uterine-, and/or adnexal-pain are reported. Ascending CT 
infections are responsible for most of the morbidity due to tubal scarring, which may result in tubal factor 
subfertility and ectopic pregnancy24,25. 
During pregnancy CT infections may lead to complications such as spontaneous abortion, preterm 
labour, preterm premature rupture of membranes, low birth weight, chorioamnionitis and postpartum 
endometritis26,27. Although reports show confl icting results about the correlation as reviewed by Baud 
et al.28.
Neonates and infants 
During delivery CT infections may be transmitted to the neonate causing conjunctivitis and pneumonia. 
The risk of maternal-fetal transmission is around 50%29-31. CT is the most common cause of neonatal 
conjunctivitis and one of the most common causes of pneumonia in early infancy. In the Netherlands 
more than 60% of the cases of neonatal conjunctivitis are causes by CT, and in 7% of the infants with 
respiratory complaints, CT was detected32,33. Symptoms of conjunctivitis develop within 2 weeks after 
delivery, and pneumonia at 4 to 17 weeks after birth. Infants with chlamydial pneumonia are at increased 
risk for later pulmonary dysfunction and possibly for chronic respiratory disease34. Besides maternally 
transmission during delivery, transmission of CT to neonates can also occur after birth.








Up to 50% of the urethral CT infections in men are asymptomatic23. CT infections in men may cause 
urethritis. Symptoms, such as dysuria and abnormal urethral discharge occur 1 to 3 weeks after exposure 
to CT. Untreated infections may lead to Reiter’s syndrome, a disorder more common in men than in 
women, consisting of arthritis, urethritis and conjunctivitis35. CT infections may also lead to epididymitis 
and prostatitis (1-4%)36. CT infections play an uncertain role in male subfertility37. Proctitis might occur, 
especially in men-who-have-sex-with-men (MSM) populations. Non-LGV-serotypes give less complaints 
(irritation, itching, (bloody) discharge, diarrhoea) than LGV strains.
Sequelae 
In the Netherlands approximately 60.000 CT infections occur each year, of which 35.000 are in women. 
Upper genital tract infection might occur (PID 5.000-10.000 each year), resulting in secondary com-
plications (tubal factor subfertility 1.000-2.000 and ectopic pregnancy 200-400 each year) (fact-sheet 
Chlamydia, stichting SOA bestrijding 1998; Screenen op Chlamydia, Rapport Gezondheidsraad 2004).
In 50% of the PIDs, CT and/or Neisseria gonorrhoeae (NG) are found38,39. In the other 50% a variety of 
bacteria is found, including enteric organisms such as Mycoplasma hominis and Ureaplasma urealyticum40. 
The diagnosis of PID is sometimes diffi cult. Around 50% of the PIDs are thought to be asymptomatic41,42. 
Thirty percent of the clinical suspected PIDs cannot be confi rmed laparoscopically43,44. The role of CT 
in the development of progressive upper genital tract pathology after repeated episodes of PID has been 
established45. There is a correlation between the severity of the PID and the incidence and the level of 
chlamydial antibody response41,42. The risk of PID following a CT infection is generally believed to 
be between 8-20%. A review of the literature showed that the PID rate differences depend on whether 
symptomatic infections were studied and the prior probability of having a sexually transmitted infection 
(STI)46. In asymptomatic women, diagnosed with a CT infection in a screening program, the PID rate 
was 0-4%, while in symptomatic women or women with a higher risk of having a STI, the PID rate was 
12-30%. 
For tubal tissue damage to occur, prolonged exposure to Chlamydia is considered a major predispos-
ing factor, either by chronic persistent infection or by frequent reinfection47,48.
After a subclinical or clinical PID, the estimated risk of ectopic pregnancy and subfertility varies 
between 5-25%24,41,49,50 and 10-20%18,51, respectively. This is based on data from high-risk populations 
and symptomatic infections. Weström et al. showed that an increasing number of PID episodes leads 
to a higher prevalence of ectopic pregnancy and subfertility24. There is reason to believe that there is 
some overestimation of the risk estimates, due to incorrect diagnosis, misclassifi cation and mistakes in 
calculations of complication rates52. Morré et al. found that the infection resolved spontaneously in the 
fi rst year after diagnosis in 45% of the untreated women53. None of the women developed signs of a PID, 
but a subclinical PID with subsequent complications cannot be excluded.
Therefore the exact prevalence of sequelae of CT infections is hard to establish. In a retrospective 
record-linkage cohort, which included Uppsala resident women aged 15-24 years between January 1985 
and December 1989, results of laboratory tests for CT, hospital diagnoses, and socio-demographic data 
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were linked. The cumulative incidence of PID by age 35 was: 5.6% (95% CI 4.7-6.7%) in women who 
ever tested positive for Chlamydia, 4.0% (3.7-4.4%) in those with negative tests, and 2.9% (2.7-3.2%) in 
those who were never screened. The corresponding fi gures for ectopic pregnancy were: 2.7% (2.1-3.5%), 
2.0% (1.8-2.3%), and 1.9% (1.7-2.1%); and for subfertility: 6.7% (5.7-7.9%), 4.7% (4.4-5.1%), and 3.1% 
(2.8-2.3%)82. This study suggests that the incidence of these complications of Chlamydia is substantially 
lower than believed54. 
Transmission and duration of infection
The risk of transmission between partners is reported to be 45-75%, with lower frequencies in those 
patients having an asymptomatic infection55,56. Some patients clear the infection spontaneously; 25% 
within 1-3 months57, and 45% after 1-year follow-up53, while in others the infection persists for years; 
46% after 1 year and 18% after 2 years58. However 94% of the women cleared the infection spontaneously 
at 4-years follow-up58. The presence of chlamydial antibodies does not mean protection against new 
infections. In contrast, it might even cause more damage because of a more severe immune response. 
Treatment and resistance
The treatment of a CT infection is simple and effective. First choice is a single dose of 1 gram azithromy-
cin. Alternatively doxycycline 100 mg twice a day, for 7 days is recommended. A meta-analysis showed 
that azithromycin and doxycycline are equally effi cacious in achieving microbial cure and have similar 
tolerability. The cure rate for azithromycin was 97%, and 98% for doxycycline59. In pregnant women 
erythromycin (1 gram twice a day) or amoxicillin (500 mg three times a day) are often prescribed as fi rst 
choice. However, azithromycin has been shown to be equally effective, safe and was associated with less 
side effects and better compliance60. In case of a symptomatic infection or PID, because of the polymicro-
bial nature, broad-spectrum regimens (oral or parenteral) are suggested, to provide adequate coverage 
against these microorganisms61.
There is some evidence of the development of antibiotic resistance62,63. However, antimicrobial 
resistance of CT is unclear and needs further research64. 
Detect ion methods 
After the detection of Chlamydia inclusions by Giemsa staining in 1907, detection methods have 
improved with respect to sensitivity, specifi city, time per assay and laboratory standardisation. From 
time-consuming and not very sensitive culture, to antigen detection methods such as enzyme immunoas-
say (EIA) and direct fl uorescent antibody assay (DFA), to more recently developed techniques such as 
nucleic acid amplifi cation tests (NAATs) and Rapid tests or Point Of Care (POC) tests. Test characteristics 
of the most widely used commercially available tests are summarised in table 2.







Table 2. Sensitivities and specifi cities of Chlamydia trachomatis detection assays (based on Bianchi et al.)65. 
(© J. Land, et al.)66.
Test Sensitivity Specifi city Detection limit
(%) (%) (no. of organisms)
NAAT 90-95 >99 1-10
DFA 80-85 >99 10-500
EIA 60-85 99 500-1000
DNA-probe 75-85 >99 500-1000
Cell culture 50-85 100 5-100
POC 25-55 >90 >10000
Culture
Although cell culture is the defi nite proof of a Chlamydia infection, making the assay 100% specifi c, it has 
some major disadvantages. The technique is very laborious, expensive and relatively insensitive (50-85%) 
as compared to the more recently developed NAATs67,68. Furthermore, for culturing the clinical material 
has to be handled in a way (regarding time, transport and storage conditions) that does not affect the 
viability of the organism. Cell culture has been regarded as the gold standard for Chlamydia infections 
but has lost this status due to the introduction of the NAATs. 
Antigen detection
i) The two target antigens used in DFA and EIA are the Chlamydia species-specifi c MOMP and the genus-
specifi c LPS (fi gure 2). Cross-reactivity is noticed on the basis of MOMP69 and LPS70, and non-specifi c 
binding occurs by reactions with host proteins. The sensitivity of DFA is 80-90% and the specifi city 
98-99% relative to culture71-73. The DFA test was widely used as a confi rmation test. Most (commercially 
available) EIA techniques are based on the immunochemical detection of LPS genus-specifi c antigen. To 
improve the specifi city, some manufacturers have developed a blocking assay in order to verify positive 
EIA results74. Currently most DFA and EIA have been replaced by NAATs. 
ii) Rapid tests or POC tests have been developed as tests which do not require sophisticated equipment 
and can be completed in about 30 minutes. Most POC tests employ EIA technology and use antibodies 
against, amongst others, LPS. They give rise to false-positive results due to cross-reactivity with LPS 
from other microorganisms. In general the POC tests are signifi cantly less sensitive and specifi c than 
laboratory-performed EIA and DFA. POC tests have been suggested to be of value for high prevalence 
ocular CT detection, but for urogenital CT infections these tests have a much too low sensitivity75.
Nucleic acid detection methods
Besides identifying Chlamydia by culture or by detecting parts of its membrane, CT can be identifi ed by 
detecting the nucleic acid (either DNA or RNA) (fi gure 2).
i) In the non-amplifi cation systems for the detection of Chlamydia DNA and RNA, for which the PACE 
2 is the best available test, sensitivity is 85-98% as compared to cell culture with a specifi city of around 
99%76-78.







Figure 2. Schematic representation of a Chlamydia particle with different targets for diagnostic tests: major outer 
membrane protein (MOMP), lipopolysaccharide (LPS), Chlamydia  plasmids (DNA and RNA), Chlamydia chromosome 
(DNA and RNA). (© J. Land, et al.) 66.
The PACE 2 (Gen-Probe) is a commercially available DNA hybridization probe for the detection of CT 
(simultaneously with NG). The probe hybridizes to a species-specifi c sequence of chlamydial 16S rRNA. 
A DNA-rRNA hybrid is formed and absorbed onto a magnetic bead. The chemiluminescent response is 
detected quantitatively by a luminometer. Actively dividing Chlamydiae contain up to 104 copies of 16S 
rRNA. The DNA probe can detect approximately 103 chlamydial elementary bodies.
ii) In the past 25 years NAATs have been developed. In these amplifi cation tests the original amount of 
nucleic acid (either DNA or RNA) present in the clinical sample is multiplied by polymerase chain reaction 
(PCR). NAATs such as PCR are very sensitive and highly specifi c. They make it possible to use noninvasive 
sampling techniques. The assays detect the extra-chromosomal CT plasmid DNA existing in ten copies 
per Chlamydia particle79. Besides the commercially available PCR assays numerous so called ‘in-house’ 
PCR assays are used. They vary greatly in performances and specifi city, and are often used in discrepancy 
analysis in comparing commercially available assays. For the detection of Chlamydia ribosomal RNA 
in amplifi cation systems, amongst others, template mediated amplifi cation (TMA) is used (GenProbe).
Since all nucleic acid amplifi cation technologies detect nucleic acid targets, they do not depend on 
either viability or an intact state of the target organism for a positive result. This might explain discrepan-
cies between culture and DNA amplifi cation tests due to nonviability of the target organism. 
Sample sites
For women it is advised to test fi rst-void urine (FVU) or a urethral specimen in combination with a cervi-
cal specimen80. Other studies found the vaginal introitus also a representative site to detect CT infections, 
with the advantage of being noninvasive81. Rectal swabs should only be obtained in women at high risk 
of being infected.
In male patients, urethral site sampling or FVU can be used for the detection of CT infections82. In 
MSM rectal samples should be taken as well, to detect more patients,







The pharyngeal sampling site does not seem to contribute much to the detection of CT infected 
patients83. It is not known whether this site has clinical implications, if standard treatment is effective 
and if the infection can be transmitted via oral sex or kissing.
Serologic tests
Different serological assays have been developed for the detection of antibodies to CT. Little is known 
about antibody profi les during acute or chronic genital Chlamydia infections. Therefore, the presence 
of CT antibodies will not distinguish a previous from a current infection. After an infection antibod-
ies persist for a long period of time84. The microimmunofl uorescence (MIF) test is the most sensitive 
serologic test for Chlamydia species and considered the ‘gold standard’ for the serological diagnosis 
of CT. It detects species- and serovar-specifi c responses. It is used for the detection of prior exposure to 
CT by the presence of IgG antibodies. However, cross-reactivity with CP in the existing assays should be 
taken into account85. The most important disadvantages are that the test is laborious and costly, and the 
reading of the assay is subjective. 
Several new commercially available species-specifi c (peptide-based) EIAs have been developed for the 
detection of CT antibodies. They seem to perform equally compared to MIF in predicting tubal pathol-
ogy86. The most accurate tests for Chlamydia antibody testing (CAT) have a sensitivity of approximately 
60% for tubal pathology while their specifi city is 85-90%87. The advantage is that the EIAs provide objec-
tive reading and allow the handling of more samples at the same time. 
IgG antibodies to Chlamydia heat shock protein 60 (cHSP60) have been suggested as markers of 
chronic infl ammation, and may therefore be good predictors of tubal pathology. These antibodies were 
found in over 70% of women with occluded tubes and in <20% of women with patent tubes88. 
Chlamydia IgG antibody testing in serum is applied in reproductive medicine in the fertility work-up 
on a large scale, but it has no place in early diagnosis of Chlamydia infections. 
Serotyping-geno typing
Currently, 19 different CT serovars and serovariants have been identifi ed by sero- and genotyping89,90. In 
conventional serotyping, after culture, polyclonal and monoclonal antibodies are used against the MOMP 
of CT91. Nowadays genotyping is performed molecular on the Omp1 gene (which encodes for the MOMP) 
by PCR-based restriction fragment length polymorphism (RFLP)92-95. 
The serovars can be divided into three serogroups: the B-group (serovars B, Ba, D, Da, E, L1, L2, and 
L2a), the intermediate group (serovars F, G, and Ga) and the C-group (serovars I, Ia, J, K, C, A, H, and L2b). 
The most prevalent CT strains worldwide are serovars D, E, and F. They account for approximately 70% 
of the typed urogenital serovars. Conjunctivitis is mainly caused by serovars A-C. In urogenital infections 
serovars D-K are predominantly isolated. Serovars L1-L3 can be found in the inguinal lymph nodes96-99. 
It is still unknown why particular CT serovars run either a symptomatic or asymptomatic clinical 
course or have a more persistent versus quickly clearing course of infection. Several studies have shown 
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relationships between specifi c serovars and clinical disease, but the results are still contradictory. It is not 
unlikely that variation at the bacterial genomic level instead of only the ompA gene could give more insight 
in the differences in virulence, tissue tropism, disease pathogenesis and epidemiology. Further more, it 
could lead to the identifi cation of strains within one serovar with different pathogenic features which 
could explain the differences in disease manifestations found in the literature for the same serovar.
Besides the use of serovar typing for epidemiology and transmission studies, also from a clinical point 
of view typing can be relevant since the LGV serovars need a three week treatment of doxycycline instead 
of one time azithromycin. 
Aims and outli ne of this thesis
In the Netherlands there are no general prevention policies for uterine instrumentation, such as curet-
tage, IUD insertion, or hysterosalpingography (HSG), for CT infections. Uterine instrumentation may 
lead to upper genital tract infections in women with CT infections. There is little information about the 
prevalence and risk factors for CT infections in a general outpatient department (OPD) of Obstetrics and 
Gynaecology (O&G) in the Netherlands. Are prevalence and risk factors for CT infections in a general 
OPD of O&G in the Netherlands comparable to other populations or other (European) countries? There-
fore, we performed a prospective, observational study in the inner city of The Hague (Chapter 2).
There is also discussion about which sample site in women is most effective in detecting CT infection. 
Is multiple site testing really necessary? We determined the incidence of multiple site or concurrent CT 
serovar infections and the prevalence of specifi c serovars in urogenital vs. rectal specimens in male and 
female patients attending a sexual transmitted disease (STD) clinic or OPD of Obstetrics and Gynaecol-
ogy (Chapter 3).
For the detection of (a past) CT infections several serological tests are available. So far they miss clinical 
evaluation. The MIF is considered the gold standard, but has several limitations. Can these new assays 
replace MIF in its role to identify those patients who need a laparoscopy for tubal pathology? Therefore, 
we compared the characteristics of two EIAs (pELISA and Chlamydia-EIA) in three well defi ned popula-
tions of women (Chapter 4). 
Chlamydia antibody testing (CAT) is nowadays used in the fertility work-up. IgG antibodies to Chlamydia 
HSP60 (cHSP60) have been suggested as markers of chronic infl ammation, and may therefore be good 
predictors of tubal pathology. We evaluated a commercially available cHSP60 serologic assay and deter-
mine the anti-cHSP60 responses in three groups of women with different degrees of tubal pathology 
(Chapter 5).







Data about specifi c serovars and the clinical course of infection, the rate of upper genital tract progres-
sion, and the clearance-persistence rate are inconclusive. We need to get more epidemiological data 
about the CT serovars and serogroups. Therefore, we focussed on the different CT serogroups and 
serovars, both to get insight in the serovar distribution within different ethnical groups (Chapter 6), and 
to get insight in the relations between the serological responses and serovars/serogroups (Chapter 7).
If we know who is at risk for CT infections and if we can identify those women with a high risk of devel-
oping upper genital tract infection and the forthcoming sequelae, we can possibly take precautionary 
measurements when intrauterine instrumentation is required and also prevent unnecessary antibiotic 
use. Hopefully in the future we will be able to describe what consequences a (previous) CT infection will 
have in an individual patient. 
The aim of this thesis was to gain more insight into all of these aspects.
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Objectives: Evaluation of prevalence and risk factors of Chlamydia trachomatis infections (CTI) in an outpa-
tient obstetrical and gynaecological population. 
Methods: A prospective, observational study was performed at an inner city hospital in The Hague, the 
Netherlands. Thirteen hundred and sixty-eight women attending the outpatient department of Obstetrics 
and Gynaecology participated in the study. For detection of CTI we used: amplifi cation of CT rRNA in 
urine samples (Gen Probe/AMPLIFIED-CT), and DNA-probe for detection of CT rRNA from a urethral, 
endocervical and anal swab (Gen Probe/PACE 2).
Results: The overall prevalence of CTI in our general obstetrical and gynaecological population was 
4.5%. The prevalence in women under 30 years of age was 8.1%. We found age and postcoital bleeding to 
be signifi cant risk factors. We did not fi nd signifi cant differences between women from different ethnic 
origin or between women using different kinds of contraceptives. Twelve (19.4%) CTI-patients were 
found positive by urine test only, and 15 (24.2%) only by DNA-probe.
Conclusions: Age is the most important risk factor in our population (overall prevalence 4.5%, preva-
lence in women under 20 years of age 15.8%). Analyses of urine and of endocervical specimens are 
complementary for the determination of the prevalence of CT infections in women. Cost-effectiveness 
analysis is needed to determine to what extent age-based screening and/or antibiotic prophylaxis before 
uterine instrumentation is indicated.
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Introduction
Chlamydia trachomatis infections (CTI) are the most common sexually transmitted infections1. CTI in 
women may cause pelvic infl ammatory disease (PID) and subsequently result in tubal factor subfertility 
and ectopic pregnancy2. Finally CTI in pregnancy may cause neonatal con junc tivitis and pneumonia3. 
Approximately 70% of the CTI in women are asymptomatic. The prevalence in asymptomatic obstetrical 
and gynaecological patients in Europe ranges from 0.8 to 4.8%4,5. Uterine instrumentation such as curet-
tage and a hysterosalpingogram in women with a CTI may cause PID as well6. In The Netherlands there 
are no general policies for uterine instrumentation. We would like to establish general policies to prevent 
intra-abdominal CTI. Therefore, information about the clinical aspects of CTI, patient characteristics and 
data on the prevalence of CTI in an outpatient department of Obstetrics and Gynaecology are needed. 
Methods
Patients
From June 1996 to September 1997, new patients attending the outpatient department of Obstetrics and 
Gynaecology of the Westeinde Hospital were requested to participate in the study. Approval was obtained 
by the ethics committee. The Westeinde Hospital is an inner city hospital, with a high percentage of 
patients from different ethnic origin. After informed consent a questionnaire was completed and a gyn-
aecologic examination was performed. 
Detection methods
For detection of CTI two methods were used: 
(i) A probe hybridisation assay from a urethral, an endocervical and an anorectal swab (PACE 2 assay) 
[Gen-Probe]. Swabs were analysed within 24 hours according to Gen-Probe’s packet insert instructions.
(ii) Amplifi cation of CT-rRNA by Transcription-Mediated Amplifi cation (TMA) in urine samples with the 
Gen-Probe AMP CT assay. Urine specimens were collected before swab specimens were gathered and 
stored at +4 ºC. The urine was analysed on a weekly basis according to Gen-Probe procedures. 
Defi nition of CTI: when either swab- or urine analysis was positive, a patient was considered positive for 
CTI at the time of sampling. 
Statistical analysis
For descriptive purposes we used cross tabulations. To estimate the probability of chlamydial infections 
as a function of the various possible risk factors we used a logistic regression model. Risk factors, as 
found in the literature and assessed by the questionnaire and gynaecological examination were entered 
into the model after which a backwards elimination was performed. Based on the fi nal model we 











computed the effects of the remaining risk factors as an estimated odds ratio and its associated 95% 
confi dence interval.
Results
During the study period 1684 patients were enrolled. A total of 276 patients refused participation for dif-
ferent reasons (16.4%), data on 40 patients (2.4%) could not be analysed (incomplete data). With regard to 
age non-responder analysis did not reveal signifi cant differences with responders. Data on 1368 patients 
were examined (table 1A). Sixty-two patients (4.5%) were found to be positive by DNA-probe and/or urine 
analysis. Of the 62 patients with a CTI the DNA-probe was positive in 48 cases. Fifteen (24.2%) patients 
with a positive DNA-probe turned out to be negative in urine analysis. Of the CTI-patients 45 were found 
positive in urine analysis. Twelve (19.4%) CTI-patients were detected by positive urine test only. 
Table 2 shows the number of CT infected women, the number of women tested and the according 
prevalence for various risk factors. The CT prevalence was inversely associated with age. An increase of 
age of one year reduces the probability of infection by 10% (OR 0.90, 95 % CI 0.87-0.94, p<0.001).
There was also a signifi cant association with postcoital bleeding. In terms of relative risk the prob-
ability of a CTI in patients with postcoital bleeding is 2.6 times as high compared to patients without this 
complaint (OR 2.6, 95% CI 1.06-6.6, p<0.04).
Table 1. Results of Gen Probe PACE 2 assay and the AMP CT assay in the detection of Chlamydia trachomatis (n).
AMPLIFIED CT (urine)
PACE 2 DNA probe Negative Positive Not determined Total 
(A) Overall results
Negative 1223 12 73 1308
Positive 15 31 2 48
Not determined 10 2 - 12
Total 1248 45 75 1368
(B) Specifi cation of positive sampling sites of the DNA probe
Endocervical 9 12 1 22
Urethral 0 6 0 6
Anorectal 3 0 0 3
Endocervical/urethral 2 7 1 10
Endocervical/anorectal 1 0 0 1
Endocervical/urethral/anorectal 0 1 0 1
Urethral/anorectal 0 1 0 1
Unknown 0 4 0 4
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Table 2. Prevalence in relation to the characteristics of the women enrolled in the trial
CT positive (n) Tested (n) Prevalence (%) p
Age (years) <0.001
<20 12 76 15.8
20-29 34 490 6.9
30-39 11 461 2.4
40-49 5 233 2.1
50-59 0 72 0
60-69 0 20 0
70-79 0 12 0
>80 0 1 0
Unknown 0 3 0
Postcoital bleeding <0.04
Yes 6 59 10.2
No 52 1241 4.2
Unknown 4 68 5.9
Ethnic origin NS
European 20 568 3.5
Mediterranean 10 275 3.6
African 4 51 7.8
Creole 5 67 7.5
Hindu 12 236 5.1
Asian 3 48 6.3
Hispanic 3 27 11.1
Other/Unknown 5 96 5.2 
Contraceptive method NS
Non 32 733 4.4
Condom 4 97 4.1
OAC 22 324 6.8
Other 3 162 1.9
Unknown 1 52 1.9
Discussion
The overall prevalence of CTI in our outpatient department of Obstetrics and Gynaecology was 4.5%, 
according with other European studies4,5. Similar risk factors as identifi ed in other populations were 
independently associated with CTI4,7. As found in other studies we found signifi cantly higher prevalences 
in younger women. If women only under 30 years of age had been tested we would have found approxi-
mately 75% of the CTI patients. If women only under 40 years of age had been tested we would have 
missed only 5 patients (8.1%). In the United States population screening is advised for women 15-24 
years of age, other studies advise age-based screening for women under 30 years of age5,8. To prevent 
complications it might be sensible to screen women in the fertile age (<40).











Our study confi rms the association between CTI and postcoital bleeding. However, since all patients 
with the complaint of postcoital bleeding and a CTI were under 30 years of age, this did not help to reveal 
more CTI patients than age-based screening alone.
We could not confi rm the relationship between CTI and ethnic origin as described in other studies, in 
which a signifi cantly higher prevalence was found in women from Suriname and the Netherlands Antil-
les9. But we do see a trend in a similar direction. An even distribution of CTI was found among patients 
using condoms or no contraceptive methods. Other studies have described lack of barrier contraceptive 
as a risk factor10. A slightly higher prevalence was found in women using oral contraceptives. 
Nearly half of the CTI patients (44%) were detected by only one of the two diagnostic tests. Since 
no discrepant analysis was performed some false positive or negative results cannot be excluded. With 
respect to the sampling site of the DNA-probe we found that most CTI patients were found positive 
on the endocervical sampling site (34 patients). Eighteen patients were found positive at the urethral 
sampling site. It is remarkable that 6 patients were found positive at the anorectal sampling site (table 
1B). For women it is advised to test urine or a urethral specimen in combination with an endocervical 
specimen11. Other studies found the vaginal introitus also a representative site to detect CTI, with the 
advantage of being noninvasive12. Anorectal swabs should only be obtained in women at high risk of 
being infected. We would have missed three CTI patients if we had used only the endocervical swab and 
the urine analysis. These three patients were found positive by anorectal swab only. If we had used only 
the endocervical and urethral swab we would have missed 15 CTI patients (12 patients only positive by 
urine analysis and three patients only positive by anorectal swab with negative urine analysis). Although 
population screening on CTI with urine analysis seems to be an easy method, we conclude that analysis 
of urine as well as endocervical specimens is essential for determination of prevalence of CTI in women. 
Although DNA amplifi cation methods used on urine specimen are reported to be so sensitive that they 
may refl ect positivity at the endocervical sampling site, our study shows discrepancies. Therefore, both 
analyses are complementary. Cost-effectiveness analysis will show whether age-based screening and/or 
antibiotic prophylaxis before uterine instrumentation will be indicated. 
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Objectives: The aims of the current study were to determine the incidence of concurrent infections on 
a serovar level, to determine the incidence of multiple anatomical infected sites on CT detection and 
serovar level, and analysis of site specifi c serovar distribution, to identify tissue tropism in urogenital vs. 
rectal specimens.
Methods: Chlamydia trachomatis (CT) infected patients in two populations were analysed in this study: 75 
patients visiting the outpatient department of Obstetrics and Gynaecology of the MC Haaglanden and 
358 patients visiting the outpatient STD clinic, The Hague, the Netherlands. The PACE 2 assay (Gen-
Probe) was used for detection of CT from urethral, cervical, vaginal, oropharyngeal, and anorectal swabs. 
CT genotyping was determined on all CT positive samples, using the CT-DT genotyping assay. 
Results: Samples of 433 patients (256 female and 177 male) with confi rmed CT infection were analysed. In 
11 patients (2.6%) concurrent serovars in one anatomical sample site were present. In 62 (34.1%) female 
and four (9.3%) male patients multiple sample site infections were found. A considerable percentage of 
women tested on the cervical/vaginal and rectal site were found positive on both sites (36.1%, 22 out of 
61). In men, D/Da and G/Ga serovars were more prevalent in rectal than urogenital specimens (p= 0.0081 
and p=0.0033, respectively) while serovar E was more prevalent in urogenital specimens (p=0.0012).
Conclusions: The prevalence of multiple serovar infections is relative low. Signifi cant differences in 
serovar distribution are found in rectal specimens of men with serovar G/Ga as the most prominent, 
suggesting tissue tropism.
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Introduction
Chlamydia trachomatis (CT) is the most prevalent bacterial sexually transmitted disease (STD) worldwide. 
Many infections are asymptomatic and, if undiagnosed and untreated, they provide a reservoir for the 
disease and long term complications1. The most common sample types are cervical, urethral, and vaginal 
swabs, and fi rst-void urine. Depending on sexual behaviour rectal and pharyngeal swabs can also be 
taken. 
Nineteen CT serovars have been identifi ed causing different types of infections; A-C cause ocular 
infections, D-K anogenital infections, and the serovars L1-L3 cause the disease lymphogranuloma 
venereum (LGV)2-4. Based on similarities on the major outer membrane protein (MOMP), the serovars 
can be divided into three serogroups, namely the B-group (serovars B, Ba, D, Da, E, L1, L2, and L2a), the 
intermediate group (serovars F, G, and Ga), and the C-group (serovars I, Ia, J, K, C, A, H, and L3). The 
most prevalent CT strains worldwide are serovars D, E, and F, accounting for approximately 70% of the 
typed urogenital serovars4-8. Serovar identifi cation is clinically important since, for example, the LGV 
serovars needs different treatment than the other ano-urogenital serovars D-K9-11.
Most of the previous studies on CT serovar distribution focused on one anatomical site, usually the 
urogenital tract. However, when there is a preference of specifi c serovars for specifi c sample sites, i.e. 
urogenital vs. rectal, serovar distributions might differ. Studies have reported 2-15% multiple serovar 
infections in one anatomical site and widespread percentages of concurrent anatomical site infec-
tion5-7,12-14. Lan et al. found 5/37 women with a single identical serovar infection in multiple sample sites 
and 2/37 women with different serovars in multiple sample sites. No concurrent infections were found 
in men15. It has been suggested that the prevalence of infection varies by anatomical site, and that serovar 
G/Ga infects more common the rectum, while others are more common in the cervix/vagina16-18. Since 
there is limited information on this subject, the current study has three aims: to determine the number 
of concurrent infections on a serovar level, to determine the percentage of multiple anatomical infected 
sites on CT detection and serovar level, and analysis of site specifi c serovar distribution, to identify tissue 
tropism in urogenital vs. rectal specimens.
Methods
Specimen collection
From January - October 2008, 433 CT infected patients in two populations were analysed in this study: 
patients visiting the outpatient department of Obstetrics and Gynaecology (OPD O&G) of the MC Haa-
glanden and patients visiting the outpatient STD clinic in the centre of The Hague, the Netherlands. The 
population was described in more detail in a serovar distribution study19.











CT detection and genotyping
For the detection of CT a probe hybridisation assay was used on urethral, cervical, vaginal, oropharyn-
geal, and anorectal swabs (PACE 2 assay, Gen-Probe). For urine analysis amplifi cation of CT-rRNA by 
transcription-mediated amplifi cation (TMA) was used in urine samples with the Gen-Probe AMP CT 
assay. 
CT amplifi cation and genotyping were performed on all samples positive for CT, using the CT-DT 
detection and genotyping assay (Labo Biomedical Products BV, the Netherlands). All analyses were 
performed according to the manufacturer’s instructions and described previously20.
Statistical analysis
Serogroup and serovar distributions were compared, using χ2 and Fisher’s Exact statistics. A p-value < 
0.05 was considered as statistically signifi cant.
Results
During the study period samples of 433 patients (256 female and 177 male) were collected sequentially 
and were used for CT serovar and typing. Three male patients were excluded because of gender and 
sample site mismatch.
Concurrent serovar infections per sampling site
In 11 patients (2.6%: 5.3 % in OPD O&G, and 2.0% (2.2% in F and 1.7% in M) in STD) concurrent serovar 
infections in one sample site were found (table 1). Eight of these eleven patients were infected with the 
serovars E, F, or serovar G/Ga. Nine patients had serovars from different serogroups. Three patients had 
different serovars from the same serogroup. In four patients it was only possible to identify the sero-
group, but not the serovar. 
Multiple sample site infections on a CT detection and serovar level
The DNA probe (PACE2) results of tested sample sites are shown in table 2. In our OPD O&G population 
all patients (n=71) were tested at both the cervical and urethral sampling sites. Twenty-seven patients 
were positive on the cervical sampling site only, 38 were positive on both sites, and six patients were 
positive on the urethral sampling site only. 
In the female STD clinic population (n=177), 168 patients were positive on the cervical or vaginal sam-
pling sites. Of the remaining nine patients, fi ve were positive on the rectal site, three on the pharyngeal 
site, and one in urine analysis. In 19.8% (n=35) of the patients only one sample was taken (27 vagina only, 
seven cervix only, and one urine only). A considerable percentage of women tested on the cervical/vaginal 
and rectal site were found positive on both sites (36.1%, 22 out of 61).
In the male STD population (n=170), 146 were positive on the urethral sampling site or in urine analy-
sis. Of the remaining 24 patients, 20 are positive on the rectal site, two on the pharyngeal site, and two 
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on both rectal and pharyngeal site. In 74.7% (n=127) of the patients only one sample was taken (98 urine 
only, 28 urethra only, and one pharynx only).
Serovars could not be determined in all DNA probe positive patients. Thirteen CT positive rectal samples 
were not available for serovar determination. 
In the remaining samples used for serovar determination multiple sample site infections were 
observed in 62 (34.1%) female (38 from the OPD O&G) and four (9.3%) male patients. In the female 
patient group 43 patients were positive on the cervix/vagina and urethra, ten on the cervix/vagina and 
rectum, eight on the cervix/vagina and pharynx, and one patient on the vagina, rectum, and pharynx. In 
the male patient group three patients were positive on the rectum and pharynx, and one patient on the 
urethra and pharynx. In all but one patient (male, rectum and pharynx) the same serovars were observed. 
Single serovar and anatomical sites
Overall, the serovars D, E and F were the most prevalent in the cervical (12.6%, 42.5%, and 25.3%, 
respectively) and urethral (11.6%, 41.9%, and 22.1%, respectively) sample sites. In all other sites serovar 
G/Ga was the third most prevalent serovar (vagina: E 34.5%, F 23.9%, and G/Ga 16.2%; urine: E 41.9%, 
Table 1. The distribution of concurrent CT serovars per sampling site.
Sample site
Sex Cervix (n=87) Vagina (n=142) Urethra (n=86) Rectum (n=47) Urine (n=105)
M# I-group (F) 
I-group (G/Ga)
M# B-group (E) 
C-group (K)
M# B-group (E) 
I-group (F)
F# I-group (F) 
C-group (?)
F# B-group (E) 
C-group (J)
F# C-group (H) 
C-group (K)
F# B-group (E) 
C-group (J)
F* I-group (G/Ga) 
C-group (?)
F* C-group (H) 
C-group (K)
F* B-group (E) 
C-group (?)
F* B-group (D/Da) 
C-group (?)
M=male, F=female; Serovars presented as Serogroup with Serovar; ?=unknown/untypeable serovar; * patients from the 
OPD O&G; # patients from the STD clinic.











F 21.9%, and G/Ga 12.4%; oropharynx: D/Da 29.4%, E 41.2%, and G/Ga 11.8%; rectum: D/Da 27.7%, E 
21.3%, and G/Ga 34.0%). In all sample sites (except rectum) serovar E was the most prevalent. 
When the serovar distribution between rectal and urogenital specimens was compared no differences for 
women were observed (Figure 1). 
In women, 16 serovars D/Da were identifi ed among 167 urogenital (cervix and vagina) specimens 
(9.6%), while in rectal specimens 3 (33.3%) serovars D/Da were observed. Although in rectal specimens 
the percentage of serovars D/Da was three times the percentage in urogenital specimens, this difference 
was only borderline signifi cant, possibly due to the low sample size of rectal infections (p=0.0592). 
In men, signifi cant differences were found for the serovars D/Da, E, and G/Ga between 25 rectal and 
140 urogenital (urethra and urine) specimens. In 28% (n=7) of the rectal specimens serovar D/Da was 
identifi ed versus 7.9% (n=11) in urogenital specimens (p=0.0081; OR 4.6, 95% CI 1.6-13.3). For serovar 
E we found 40.7% (n=57) in urogenital specimens and 8% (n=2) in rectal specimens (p=0.0012; OR 7.8, 
95% CI 1.8-35). And in the male rectal specimens 10 contained serovar G/Ga (40%), while 19 urogenital 
specimens (13.6%) contained serovar G/Ga identical to the percentage found in women (p=0.0033; OR 
4.2, 95% CI 1.7-11). 
Table 2. Multiple site infections (DNA probe (PACE2) positive) in male and female patients tested at multiple sample sites. 
Female* All sites Male‡ All sites
Sample sites Tested (n) positive (n) % Tested (n) Positive (n) %
Cervix/Vagina + 
Urethra
75 43 57,3 - - -
Cervix/Vagina + 
Rectum
29 19 65,5 - - -
Cervix/Vagina + 
Pharynx








1 1 100 - - -
Urethra/Urine + 
Rectum
- - - 39 5 12,8
Urethra/Urine + 
Pharynx
- - - 41 1 2,4
Rectum 
+ Pharynx




- - - 39 1 2,6
* All, but one female patient (tested urine only) were tested on the cervical/vaginal sample site. ‡ All, but one male patient 
(tested at pharyngeal site only) were tested at the urethral site/urine.
This table shows combinations of sample sites. Some patients were tested at more sites than the two mentioned, but the 
third site was then always negative. i.e. female cx/vag + rc n= 32 tested, but 31 were also pharynx tested and 1 urethra.
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All 25 men of which rectal samples were taken were men-who-have-sex-with-men (MSM). Fourteen 
out of the 140 males were MSM in the group from which urogenital specimens were obtained. In these 14 
men we found 6 serovars D/Da, 3 serovars G/Ga, 4 serovars J, and 1 serovar F.
Discussion
Concurrent serovar infections per sampling site
A prevalence of concurrent serovar infections (2.6%) in the same (low) range as detected in other studies 
was found5-7,12-14. Barnes et al. describe seven (2%) multiple serovars; three (1.4%) of 213 cervical swabs 
of women visiting a STD clinic, three (10%) of cervical swabs of jailed women (mostly prostitutes), and 
one (0.9%) of 109 rectal swabs of MSM attending a STD clinic21. In the current study none of the women 
Figure 1. Serovar D/Da, E and G/Ga distribution in females and males in urogenital vs. rectal specimens.











with multiple serovars were engaged in prostitution. One of the three men with multiple serovars was 
bisexual, the remaining two were heterosexual. 
In some patients it was only possible to identify the serogroup, but not the serovar. This is probably 
due to a new genovariant of the serovar which does not respond to the specifi c serovar probe, but does 
respond to the more conservative serogroup probe. Also, an infection with multiple serovars within the 
same serogroup can be caused by a new genovariant. For example, a new genovariant of serovar K was 
revealed by sequencing potential multiple infections of serovar H&K (both serogroup C) in women visit-
ing a women’s health clinic in Uganda20. This leads to the recommendation to sequence multiple infec-
tions belonging to the same serogroup, to exclude new variants (not performed in the current study).
Multiple sample site infections
In 72 (33.8%) of the female patients in which multiple samples were taken, DNA probe (PACE 2) results 
were positive on more than one site. In nine (20.9%) of the male patients in which multiple samples were 
taken, DNA probe (PACE 2) results were positive on more than one site. All male patients were MSM. 
Kent et al. describe multiple site infections in 48 (10.5%) patients in a population of MSM who have been 
tested at three sites (rectum, urethra, and pharynx). In MSM who had only been tested at the urethral and 
pharyngeal site only two (1.6%) were found positive at two sites, possibly caused by a lower CT prevalence 
(7.1% vs. 13.3%)16. 
In 66 patients serovars at multiple sample sites were positive. Dean et al. found 21% (n=7) of women 
to be positive at the cervical and endometrial sampling site6. Since in all but one patient the same serovar 
was found, serovars analysis at one sample site seems to justifi able. 
In female patients, cervix or vagina sampling revealed 94.9% of the CT infected patients. Sexual 
behaviour questionnaires help to reveal the other sample sites (rectum and oropharynx). In male patients, 
urethral site sampling or urine revealed 85.9% of the CT infected patients. In MSM rectal samples are 
taken as well, to detect more patients, since the proctum can be a reservoir of CT infections. The pharyn-
geal sampling site does not seem to contribute much to the detection of CT infected patients.
Serovar and anatomical sites
Worldwide, serovars D, E, and F are most prevalent, but there are some demographic changes4,5. 
Serovar E was the most prevalent, in our study, as well as in others4,5. In our study, we found serovar G/
Ga to be the third most prevalent serovar after D and E, in most sampling sites. CT has been identifi ed as 
a co-factor of cervical neoplasia22. A previous study had demonstrated an association between CT serovar 
G antibodies and squamous cell carcinoma23. In adenocarinoma of the cervix no co-infection of CT and 
Human Papillomavirus was found24. The prevalence of serovar G/Ga was the lowest (5.7%) at the cervical 
sampling site in our study. Similar to our results, Lan et al. found serovar G as the third most prevalent 
serovar in young women visiting an OPD of Obstetrics and Gynaecology20,25. In some Asian countries 
higher prevalences of serovar G are observed (7-15%)26. These prevalences are observed mostly in STD 
clinic populations, but also in obstetrical and gynaecological patients (14.9%).
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In men, serovars D/Da and G/Ga were signifi cantly more prevalent in rectal than in urogenital swabs 
(28% vs. 7.9% and 40% vs. 13.6%). In women a similar tendency was observed for these serovars, 
although not signifi cant (33.3% vs. 9.6% and 22.2% vs. 13.8%). In men, serovar E was more prevalent in 
the urogenital swabs than in the rectal swabs (40.7% vs. 8%), while in women it was approximately the 
same (35.3% vs. 44.4%), and in normal range as compared to other Dutch studies. The serovars B/Ba, H, 
I/Ia, and K were not determined in the rectal swabs in both men and women. In women serovar J and F 
were not found in rectal swabs. 
All 25 rectal samples obtained from male patients in our study were from MSM. Serovar G/Ga was 
signifi cantly more prevalent in this group, followed by serovar D/Da. In 14 MSM urogenital samples were 
taken. Serovar D/Da was most prevalent (42.9%) followed by serovar J (28.6%) and serovar G/Ga (21.4%). 
In female rectal specimens serovar E was most frequently detected. 
Similar results were described by Barnes et al.18. The rectal swabs were obtained from MSM. They also 
tested the rectal swabs of 32 women and found two serovars B, one I/Ia, and one K. In our study those 
serovars were not identifi ed in men or women. It is suggested that these serovars are less viable in the 
rectum. The permeability to toxic substances could be infl uenced by the porin activity of the major outer 
membrane protein (MOMP), therefore serotype might refl ect organism permeability18,27.
Two explanations for the prevalence differences between rectal and urogenital specimens, not mutually 
exclusive are present: 1) serovars G/Ga and D/Da have a higher affi nity to epithelial cells of the rectum 
compared to urogenital epithelial cells, potentially partially mediated by the environment, suggesting 
tissue tropism, still based on unknown virulence factors, and 2) the high incidence of serovars G/Ga 
and D/Da in rectal specimens of MSM can fi nd its origin in differences in sexual behaviour and group 
dynamics compared to heterosexuals. However, since in the heterosexual women included in our study 
the same trend was found, serovar distribution linked to core groups is less likely as an explanation. 
Other studies fi nd similar results; most rectal Chlamydia infections were caused by serovar G/Ga (47.9%) 
in MSM, while in the same population the prevalence of urogenital serovar G/Ga for men and women 
was much lower (16% vs. 11% resp.)17,28. In San Francisco, rectal specimens of MSM were tested in two 
populations16. The prevalence of CT infections was 8.8% and 5.7% in patients visiting a STD clinic and 
a Gay men’s health centre, respectively. Unfortunately, no serovar analysis was performed. Barnes et al. 
describe signifi cant higher prevalences of serovar G/Ga in cervical isolates of heterosexual women and 
rectal isolates of MSM18. The prevalence of serovar G/Ga (13%) in the rectal isolates is however signifi -
cantly lower than in our study (40%) (p=0.0026). 
Recently, Jeffrey et al. demonstrated that polymorphisms in open reading frame sequences have a 
correlation with different tissue tropisms of serovars. Genome sequence analysis is an effective approach 
to discover variable loci in Chlamydiae that are associated with clinical presentation29.
In conclusion: the prevalence of multiple serovar infections at different sites of the same individual is 
relatively low. Therefore serovar analysis could be performed on one positive sample site. Signifi cant dif-
ferences in serovar prevalences are found between rectal and urogenital specimens in men. The serovar 











distribution in rectal specimens of MSM showed signifi cant differences, with serovar G/Ga as the most 
prominent. 
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New serological enzyme immunoassays (EIAs) were compared with microimmunofl uorescence (MIF) 
as ‘gold standard’ to detect Chlamydia trachomatis (CT) antibodies in different groups of obstetrical, gyn-
aecological and subfertile patients. There were no signifi cant differences in seroprevalence rates, except 
for the group of CT-positive patients (p<0.01). Test characteristics were calculated for Chlamydia-EIA 
(Biologische Analysen-system GmbH, Lich, Germany) and pELISA (Medac, Wedel, Germany). pELISA 
seems to be a good alternative to MIF. It has high specifi city and is easier to perform. 
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Introduction
Recently new commercially available species-specifi c (peptide-based) enzyme immunoassays (EIAs) have 
been developed for the detection of Chlamydia trachomatis (CT)-antibodies. So far they have missed clinical 
evaluation. Serological assays have been used to detect antichlamydial antibodies in the fertility work-
up10, predicting tubal pathology5,7. Their value for fertility evaluation remains the subject of debate. There 
is wide variation between various tests in the correlation of antichlamydial antibodies with current CT 
infections or tubal pathology. The species-specifi c microimmunofl uorescence assay (MIF) is considered 
to be the ‘gold standard’ for the serological diagnosis of CT infections12. Cross-reactivity with Chlamydia 
pneumoniae in the existing assays should be taken into account3. MIF is laborious and reading subjective, 
and therefore it is not suitable for a daily routine. EIAs provide objective reading and allow the handling 
of more samples at the same time. We compared two new serological assays with MIF to determine the 
performance of these assays in the routine serodiagnosis of CT infections. 
Methods
For our serological studies, we divided sera from obstetrical and gynaecological patients into four dif-
ferent groups: subfertility patients (n=76), pregnant women (n=150), a control group which includes 
a randomly selected group of women who visited our outpatient department with various complaints, 
unrelated to subfertility or pregnancy (n=220), and women found positive for CT in a direct antigen assay 
(n=40). Some women in the last group were also represented in the subfertility or pregnant group (n=2 
and n=5, respectively).
For serological diagnosis, we used two EIAs. The CT-pELISA (Medac, Wedel, Germany) was used to 
perform species-specifi c serology by using a synthetic peptide from the immunodominant region of the 
major outer membrane protein. This highly specifi c antigen makes it possible to discriminate between 
CT-specifi c antibodies and the whole anti-chlamydia antibody response.
The BAG-Chlamydia-EIA (Biologische Analysensystem GmbH, Lich, Germany) uses the ultrasoni-
cated whole cell CT antigen (strain LGV Type 17). If CT antibodies are present in the specimen, they will 
react with the antigen. Both microtiter assays use peroxidase-conjugated antihuman immunoglobulin 
G (IgG) and IgA antibodies to bind to CT IgG and IgA antibodies. After incubation with tetrameth-
ylbenzidine substrate, the reaction is stopped by the addition of sulfuric acid. The absorption is read 
photometrically at 450 nm. The intensity of the colour is proportional to the concentration (or titer) of 
the specifi c antibody in the sample. 
Cut-off values were calculated according to the manufacturer’s instructions. Results in the grey-zone 
were considered negative in the calculations.











An indirect MIF antibody technique was used as a gold standard to detect CT IgG-antibodies (egg-grown 
CT biovar L2; BioMérieux, ‘s Hertogenbosch, the Netherlands). Sera were diluted to a titer of 1:64 in 
phosphate buffered saline (PBS). After incubation and washing in PBS, a conjugate (Fluoline-G; Evans 
blue diluted in PBS) was added to the samples. After 30 minutes incubation at 37ºC and washing in PBS, 
the slide was covered with a coverslip with a mounting medium. A fl uorescence microscope was used 
for the reading of the slides. A positive reaction is a ‘starry sky’ appearance: fl uorescent green spots on a 
slightly red background. Two experienced persons evaluated all samples. When discrepancies occurred a 
third person evaluated the sample.
For comparison of the EIAs to the MIF assay and to detect tubal pathology, two-by-two tables were 
used to calculate sensitivity, specifi city, positive predictive value (PPV) and negative predictive value 
(NPV). The chi-square test was used to test the signifi cance of the difference in frequency distribution. A 
p-value of < 0.05 was considered signifi cant. 
Results
The seroprevalence rates in the subfertility, pregnant and control group are described in table 1. No 
signifi cant differences in overall prevalence rates of CT IgG antibodies were found in all three assays. 
The prevalence of CT IgA antibodies is very low. Signifi cantly higher prevalences of CT IgG antibodies 
were found in the group of CT-positive patients (p<0.01) (table 1). Also, a signifi cant (p<0.05) increase 
of the prevalence of CT IgA antibodies was found. The Chlamydia-EIA has a good correlation with the 
prevalence of CT IgG antibodies. This assay detected the highest percentage of CT-positive patients 
(82.5%). The test characteristics of the two EIAs are described in table 2. 
Table 1. Prevalence of C. trachomatis antibodies (IgG and IgA) using different detection assays in different gynaecological 
patient groups. 
Prevalencea





























a Values are percentages. Each parenthetical value is n.
b Sera diluted to a titer of 1:64.
Tubal patency is essential for fertility. Patency is tested either by visualizing the tubes by X- ray with con-
trast fl uid (hysterosalpingography) or by direct observation by laparoscopy during which the tubes are 
pertubated. In 32 subfertility patients tubal patency was tested. Twenty-one patients had patent tubes. In 
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14 of these patients, no CT IgG antibodies were found (67%). In 11 patients, tubal pathology was found. 
However, in three patients, none of the assays showed presence of CT IgG antibodies (27%). There was a 
signifi cant difference in serology in the MIF assay between the patients with tubal pathology versus those 
without (p<0.02). Table 3 shows the test characteristics of the three assays as predictors of tubal pathology. 
Table 2. Test characteristics of the Chlamydia-EIA and pELISA in relation to MIF in different groupsa
Subfertility Pregnant Control
Parameterb Chlamydia-EIA pELISA Chlamydia-EIA pELISA Chlamydia-EIA pELISA
Sensitivity 66.7 58.3 77.1 62.9 76.8 47.8
Specifi city 84.6 96.2 91.3 96.5 89.4 94
PPV 66.7 87.5 73 84.6 76.8 78.6
NPV 84.6 83.3 92.9 89.5 89.4 79.8
a MIF (IgG) was used as the gold standard.
b For all parameters, values are percentages.
Table 3. Test characteristics of the Chlamydia-EIA, pELISA and MIF in relation to tubal pathology (IgG).
Result
Parametera Chlamydia-EIA pELISA MIF
Sensitivity 54.6 36.4 63.6
Specifi city 71.4 85.7 81
PPV 50 57.1 63.6
NPV 75 72 81
a For all parameters, values are percentages.
Discussion
There is little literature available describing performance of new assays. pELISA has been evaluated in 
infertility patients especially to describe its role in predicting tubal factor infertility4,8,9. Blood samples 
from healthy female blood donors or pregnant women were commonly used as controls. In our subfertil-
ity group, the prevalence rates of CT IgG and IgA antibodies according to the pELISA and MIF assay 
were lower than described in other studies using the pELISA1,3,6,8,9. However, in other studies, the titer 
at which the MIF assay is considered positive is often not mentioned. A lower titer will give more false-
positive results. Another reason for the lower prevalence rate in our subfertility group might be that this 
group includes only a small number of patients with tubal factor infertility (TFI) (n=11), where in other 
groups, larger numbers of TFI patients were found. Therefore, comparison with non-TFI patients might 
be more applicable. 
The prevalence rates of CT IgG and IgA antibodies found in our group of pregnant women are in the 
same range as found in other studies for the pELISA and slightly higher than those for the MIF assay1,8,9. 
Our control group differs from other control groups, since it includes women visiting the Obstetrics 
and Gynaecology Outpatient Department for various complaints. When we compare our group with 











blood donors and other asymptomatic patients, we fi nd for the pELISA IgG and MIF a higher prevalence 
rate and for the pELISA IgA prevalence in the same range1,6,9. 
Regarding our group of CT-positive patients, the pELISA shows approximately the same prevalence 
rates, while using the MIF assay, we found a lower prevalence1,6. 
We have no explanation for the lower prevalence and sensitivity found using the pELISA in all patient 
groups. We did not fi nd any study describing the performance of the Chlamydia-EIA. 
By using the MIF assay as the gold standard, the test characteristics of the Chlamydia-EIA and pELISA 
for the determination of serological evidence of a recent or past CT infection therefore depended on the 
patient group tested (table 2). Both tests have reasonably high specifi city and NPV and would therefore 
match the criteria of a screenings test. We have to consider that cross-reactivity with other Chlamydia 
species also occurs for the MIF assay 3,11.
When serology is used to detect tubal pathology, high specifi city is important. However, when we 
used tubal pathology as the gold standard, the specifi city and NPV are somewhat lower (table 3). We 
have to consider that these results are based on a small number of patients (n=32). In the patients with 
patent tubes, 33% had CT IgG antibodies, and in patients with tubal pathology, 27% had no CT IgG 
antibodies. Therefore, none of the three assays we used appeared to be perfectly able to predict tubal 
pathology. Gijsen et al. described no signifi cant differences between two peptide-based EIAs and the MIF 
in predicting tubal pathology4. Our test results were comparable, with the exception of the pELISA, which 
showed a lower sensitivity and a higher specifi city. 
And what about the IgA antibodies? In patients with a current CT infection low prevalence rates of IgA 
antibodies are found (table 1). It seems that the IgA antibodies can persist for years, even after effective 
therapy2. Therefore, IgA antibodies do not indicate a current CT infection. The role of IgA antibodies in 
the serodiagnosis of CT with the currently available assays remains negligible.
pELISA seems to be a good alternative for MIF for the detection of CT antibodies. pELISA is more species-
specifi c than the Chlamydia-EIA. It is less laborious and less expensive than MIF. A screenings test needs 
high specifi city and high NPV. When the two assays are compared with MIF as the gold standard, pELISA 
has the highest specifi city, and in the subfertility group, it has a NPV comparable to that of Chlamydia-
EIA. 
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Introduction
Besides commercially available serological assays that detect antibodies to major outer membrane 
protein (MOMP)1 and lipopolysaccharide (LPS) ‘in-house’ chlamydial heat shock protein 60 (cHSP60) 
assays are extensively used in assessing serological responses to urogenital Chlamydia trachomatis (CT) 
infection. Although comparison of the different ‘in-house’ assays is diffi cult owing to a lack of stan-
dardisation, there is a consensus among the users of these assays that the anti-cHSP60 responses in 
women increase with the severity of CT associated disease, leading to the suggestion that the high amino 
acid sequence homology between chlamydial and human HSP60 results in autoimmune mediated fal-
lopian tube damage. Owing to the signifi cance of the possible association of the response to cHSP60 and 
progressive disease, a commercially produced assay that employs defi ned cHSP60 epitopes should allow 
for the comparison of results obtained in different laboratories, as well as forward the use of cHSP60 
as a diagnostic tool, if the assay proves to be relevant in predicting pathology or clinical outcome of a 
urogenital chlamydial infection. 
This study evaluated a recently introduced commercially available cHSP60 serologic assay and deter-
mined the anti-cHSP60 responses in three gynaecologically well defi ned groups of women.
Methods
Group 1 consisted of women without tubal pathology as assessed by either hysterosalpingography 
(HSG) or laparoscopy (n=21), group 2 consisted of pregnant women (unknown tubal status, proven 
fertility; n=86), and group 3 consisted of women with confi rmed (based on HSG or laparoscopy) tubal 
pathology (n=11). CT positivity was assessed previously using one of the following serological assays: 
microimmunofl uorescence (MIF) (BioMérieux, ‘s Hertogenbosch, the Netherlands), BAG Chlamydia 
EIA (Biologische Analysensystem GmbH, Lich, Germany) and the CT-pELISA (Medac, Wedel, Germany). 
The study groups and techniques described previously2,3. The cHSP60 assay (Medac, Wedel, Germany) 
was performed according to the manufacturer’s instructions.
Results
Results are shown in fi gure 1. CT IgG positivity was previously determined to be 19% for group 1, 40% 
for group 2, and 64% for group 3, showing the expected clear difference in IgG seroprevalence between 
women with and without procedure confi rmed tubal pathology, while an intermediate prevalence was 
observed in pregnant women. The same pattern but with lesser incidence was observed in the anti-
cHSP60 responses being 4.8%, 16% and 27%, for groups 1-3, respectively (χ2 test for trend: χ2=3.1, 
p=0.079, group 1 vs. group 3: p=0.096, OR 10.6). The incidences of anti-cHSP60 were increased in the 
CT IgG positive subgroups to 25%, 35% and 43%, for groups 1-3, respectively (see lower panel in fi gure 











1), while only 3.8% anti-cHSP60 titers were observed in the CT IgG negative subgroups, all in subgroup 
2 (unknown tubal status, proven fertility). This indicates that the concordance between CT IgG and 
cHSP60 positivity is high, almost 90%, however, clearly a different subgroup of women is identifi ed by 
the cHSP60 assay since only 40% of the CT IgG positive women has a cHSP60 response (measurement of 
agreement: kappa 0.371). Finally, the median cHSP60 titers increased from group 1-3: 50, 100 and 200, 
respectively, suggesting an association between the level of cHSP60 response and tubal pathology.
Discussion
As far as we know this is the fi rst study evaluating the commercially available cHSP60 assay in women 
with different degrees of tubal pathology. Two abstracts were published in the ISSTDR meeting Vienna, 
Austria in 20024,5 on cHSP60 antibodies in women with pelvic infl ammatory disease (85% in patients 
with CT positive swabs and patients with occluded tubes, 20% in blood donors) and in women with open 
or occluded fallopian tubes (31% and 70% respectively).
The standardisation provided through this new commercially available assay will potentially enhance 
the comparability of cHSP60 results between laboratories. The results presented here, although obtained 
in small but well defi ned groups, look suggestively promising. Indeed, power calculations (alpha =0.5, 
beta=0.1) show that doubling (1.7 times) the size of the (sub)groups would results in signifi cant p-values 
instead of clear trends. However, further studies are needed in larger groups with different degrees of 
pathology because of CT infections, to further determine the diagnostic, prognostic and clinical relevance 
of this new assay. 
Figure 1. Chlamydia trach different degrees of tubal p omatis IgG and cHSP60 antibody responses in Dutch Caucasian 
women with athology
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Objectives: The Chlamydia trachomatis (CT) serovar distribution is stable in time, however geographical 
differences in the distribution are observed. These differences might be due to differences in the ethnical 
composition of the population. The fi rst objective of this study is to determine the CT serovar distribution 
among different ethnic populations in the region The Hague in two cohorts and to compare the results 
to previous obtained Dutch serovars distribution studies. The current study will elucidate the potential 
association between ethnicity and presence of different serovars. Secondly, the association between 
serogroup distribution and various demographical, clinical, and behavioural parameters (i.e. population, 
symptoms and age) was investigated.
Methods: A total of 418 CT infected patients in two populations were analysed in this study: patients 
visiting the outpatient department (OPD) of Obstetrics and Gynaecology (O&G) of the MC Haaglanden 
and patients visiting the outpatient STD clinic in the centre of The Hague, the Netherlands. 
Results: Serovar E, F, and G/Ga were the most prevalent serovars, accounting for 73.2% of the serovars. 
No strong relation was found between ethnicity and serovars/serogroups. For serovar H and I/Ia differ-
ences were observed with earlier Dutch studies. Finally, no relation between the demographical, clinical, 
and behavioural variables and serovars were found.
Conclusions: This is the fi rst Dutch serovar study taking ethnicity into account and the second largest 
study on CT serovar distributions in the Netherlands. No major differences were observed between the 
different ethnic groups studied. We did fi nd some differences in serovar distribution compared to previ-
ously published Dutch serovar studies. Finally, our results suggest that the infecting serovar does not 
have a major impact on the clinical presentation of infections.
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Introduction
Chlamydia trachomatis (CT) infections are one of the most common bacterial sexually transmitted diseases 
(STD) worldwide. In many cases the infections are asymptomatic in both men and women, and therefore 
undiagnosed and untreated. Nevertheless, asymptomatic infections still contribute to the distribution 
of a CT infection to others, in which it can give symptoms. Also, untreated CT infections may lead to 
late disease like pelvic infl ammatory disease (PID), a major cause of ectopic pregnancy and tubal factor 
subfertility1.
Currently, 19 different CT serovars and serovariants have been identifi ed by sero- and genotyping2,3. In 
conventional serotyping, after culture, polyclonal and monoclonal antibodies are used against the major 
outer membrane protein (MOMP) of CT4. The serovars can be divided into three serogroups: the B-group 
(serovars B, Ba, D, Da, E, L1, L2, and L2a), the intermediate group (serovars F, G, and Ga) and the C-group 
(serovars I, Ia, J, K, C, A, H, and L3). 
Based on tissue tropism, the majority of serovars A-C cause a conjunctivitis, while serovars D-K are 
predominantly isolated form the anogenital tract. The serovars L1-L3 are more invasive serovars and can 
cause a Lymphogranuloma venereum (LGV)5-8.
Untill recently, genotyping was performed molecular on the Omp1 gene (which encodes for the MOMP) 
by polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP)9-12. 
Nowadays, several reverse line blots have been developed mostly based on amplifi cation within the 
Omp1 gene13,14.
An increasing number of isolates are typed worldwide and provide a wealth of information on the epide-
miology of CT infections. Several studies have described inconclusive data about specifi c serovars and the 
clinical course of infection, the rate of upper genital tract progression, and the clearance-persistence rate.
Information about the differences in serovar distribution could give information about the epidemiol-
ogy of CT infections and might have clinical implications5,7,15-18. Certain serovars might be associated 
with upper genital tract infection. And, for example, LGV strains need a different and longer therapy 
(up to three weeks) than other serovars. A recent study about serovar distribution in the Netherlands 
showed no signifi cant serovar distribution shift over time, but geographical differences were observed. 
This could be the result of different ethnic composition19,20. The current study will contribute to our 
understanding if differences in the serovar distributions found are in part ethnicity-based.
The objective of this study is to determine the CT serovar distribution among different ethnic popula-
tions in the region The Hague in two cohorts and to compare the results to previous obtained Dutch 
serovars distribution studies. The association between serovar distribution and various demographical, 
clinical, and behavioural parameters will be investigated as well.













CT infected patients in two well defi ned populations were analysed in this study: patients visiting the 
outpatient department (OPD) of Obstetrics and Gynaecology (O&G) of the MC Haaglanden and patients 
visiting the outpatient STD clinic in the centre of The Hague, the Netherlands. 
i) OPD Obstetrics and Gynaecology, MC Haaglanden, The Hague; 
MC Haaglanden is an inner city hospital with patients from various ethnic origins. Patients visited 
the OPD O&G for various reasons, for example pregnancy, discharge, menstrual disorders, subfertility, 
contraception etc. If required, cervical and urethral swabs were taken. Samples from CT infected patients 
were used in this study in the period January - October 2008.
ii) STD clinic, The Hague; 
During the same study period samples from CT infected patients (men and women) visiting the STD 
clinic were analysed in the study. Patients could be visiting because of complaints, because they were 
warned by an infected partner, or for check-up. In women cervical or vaginal swabs were taken, and in 
some women urethral swabs or fi rst-void urine (FVU). In men, urethral swabs or FVU was collected. In 
men-who-have-sex-with-men (MSM) anorectal and oropharyngeal swabs were taken as well. In women 
these swabs were taken when oral or anal sex was reported. 
In both clinics information was collected concerning age, gender (STD clinic only, OPD all female), 
ethnicity, symptoms (symptomatic, asymptomatic, or upper genital tract infection), and co-infections 
(such as gonorrhoea, hepatitis B, HIV, Syphilis, Mycoplasma, Gardnerella, and Candida). 
All patient and sample data were anonymised by each center and analysed according to local ethical 
regulations. 
CT detection
For the detection of CT we used a probe hybridisation assay on urethral, cervical, vaginal, pharyngeal, 
and rectal swabs (PACE 2 assay, Gen-Probe). Swabs were analysed within 24 hours according to Gen-
Probe’s packet insert instructions. For urine analysis we used amplifi cation of CT-rRNA by transcription-
mediated amplifi cation (TMA) in urine samples with the Gen-Probe AMP CT assay. Urine specimens 
were collected before swab specimens were gathered and stored at +4 ºC. The urine was analysed on a 
weekly basis according to Gen-Probe procedures.
Amplifi cation, detection, and genotyping using the CT DT assay
The CT-DT amplifi cation and genotyping assay was performed on all previous determined CT positive 
samples according to the manufacturer’s instructions (Labo Biomedical Products BV, The Netherlands). 
The CT-DT genotyping assay is a reverse hybridization probe line blot (RHA) with a probe for the detec-
tion of the cryptic plasmid, and probes to detect the 3 different CT serogroups (B, C, and Intermediate) 
and the 14 major serovars (A, B/Ba, C, D/Da, E, F, G/Ga, H, I/Ia, J, K, L1, L2/L2a, and L3)14.
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Studies used for comparison
Spaargaren et al. describe the serovar distribution in a STD population in Amsterdam19. They also com-
pare serovar distributions in the Netherlands, found in nine studies between 1986-2002. Populations 
included were a STD population, asymptomatic screenings population and mixed symptomatic and 
asymptomatic patients in Amsterdam, and a STD population in Rotterdam. The type of cohort did not 
infl uence the analyses. However, serovar distribution differences were found between Amsterdam and 
Rotterdam (C-group, especially serovar K, Intermediate group, especially serovar F). 
Morré et al. describe CT serovar distributions in symptomatically and asymptomatically infected 
patients in Amsterdam, identifi ed in a general practitioners screenings program and a hospital outpa-
tient-based CT infected population6.
Statistical analysis
Serogroup and serovar distributions were compared between men and women, and between Dutch 
cohorts, using χ2 statistics. A p < 0.05 was considered statistically signifi cant. Bonferroni correction 
was used for multiple comparisons and Mann-Whitney U test, if applicable, using Graph Pad InStat 3.
Results
During the study period samples were collected sequentially. Samples of 433 patients could be used for 
CT serovar detection and typing. Patients were excluded because of concurrent serovar infection in one 
sample site (n=11), different serovars in different sample sites (n=1), and mismatch sex and sample site 
(n=3). A total of 418 patients were used for further analysis. 
Ethnicity
We compared serogroup distributions in different ethnic groups (Dutch Caucasian (DC)), Surinam, 
Netherlands Antilles (NA) and Turkish/Moroccan). Results are shown in table 1. No signifi cant differ-
ences were found between the ethnic groups, although one comparison was borderline signifi cant; the 
B-group and the intermediate group vs. the C-group for DC vs. NA patients (p=0.09; OR 2.1 (95% CI 
0.95-4.8).
In CT infected patients, no differences were observed in the age distribution between patients visiting the 
O&G department and women visiting STD outpatient clinic. In the STD clinic population signifi cant dif-
ferences were found between male and female patients for DC and NA patients (p<0.0001 and p=0.0416, 
respectively). Male patients were older. In the STD clinic patients it was found that Surinam patients were 
signifi cantly younger than DC patients (p=0.0324), and this was mainly caused by the male Surinam STD 
clinic patients (p=0.0158). Within the O&G patients no signifi cant differences between ethnic groups 
were determined.











Table 1. Serogroup distribution and median age in different ethnic groups.
Serogroups
Ethnicity B n(%) Intermediate n(%) C n(%) Total n
Dutch Caucasian 125 (52,3) 80 (33,5) 34 (14,2) 239
Netherlands Antilles 14 (36,8) 14 (36,8) 10 (26,3) 38
Surinam 11 (42,3) 12 (46,2) 3 (11,5) 26
Turkish/Moroccan 12 (46,2) 11 (42,3) 3 (11,5) 26
Median age (range)
Ethnicity O&G STD total STD F STD M
Dutch Caucasian 22 (17-47) 24 (16-72) 22 (16-61) 27 (18-72)
Netherlands Antilles 22.5 (15-35) 23.5 (18-36) 22 (19-27) 27 (18-36)
Surinam 27.5 (18-44) 21.5 (15-42) 21.5 (15-37) 21.5(19-42)
Turkish/Moroccan 25 (18-44) 25.5 (19-39) 23 (19-39) 26 (24-36)
Table 2. Serovar distribution in Dutch patients divided in serovars and serogroups and by gender. Previously published 
results in Dutch cohorts (19,6) are given for comparison.
This study Spaargaren et 
al. 2004











B 2(0.8) - 2(0.5) 4(1.0) - - -
D/Da 32(12.9) 19(11.2) 51(12.2) 50(12.3) 41(12.9) 12(10.8) 53(12.4)
E 95(38.3) 60(3 ) 155(37.1) 136(33.4) 130(41.0) 47(42.3) 177(41.4)
Subtotal 129(52.0) 79(46.5) 208(49.8) 190(46.7) 171(53.9) 59(53.2) 230(53.7)
I group
F 58 (23.4) 32(18.8) 90(21.5) 95(23.3) 72(22.7) 21(18.9) 93(21.7)
G/Ga 31(12.5) 30(17.7) 61(14.6) 38(9.3) 24(7.6) 12(10.8) 36(8.4)
Subtotal 89(35.9) 62(36.5) 151(36.1) 133(32.7) 96(30.3) 33(29.7) 129(30.1)
C group
H 3(2.1) - 3(0.7) 34(8.4) 9(3.4) 7(6.3) 16(3.7)
I/Ia 6(2.4) 3(18) 9(2.2) 30(7.4) 11(3.5) 6(5.4) 17(4.0)
J 16(6.5) 18(10.6) 34(8.1) 12(2.9) 17(5.4) 2(1.8) 19(4.4)
K 5(2.0) 8(4.7) 13(3.1) 8(2.0) 13(4.1) 4(3.6) 17(4.0)
Subtotal 30(12.1) 29(17.1) 59(14.1) 84(20.6) 50(15.8) 19(17.1) 69(16.1)
Total 248 170 418 407 317 111 428
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Serovar distribution compared to other Dutch studies
The most prevalent serovars were E, F, and G/Ga, they accounted for 73.2% of the serovars. 
There was no signifi cant difference in serovar distribution between male or female patients, nor 
between patients from the STD clinic or OPD Obstetrics and Gynaecology. The distribution of serovars is 
shown in table 2. We compared our serovar distribution to serovar distributions of other Dutch cohorts.
[6,19] Serovar H and I/Ia showed signifi cant differences with Spaargaren et al. (H: p<0.0001 and I/Ia: 
p=0.0004). After Bonferroni correction this was still signifi cant.
Serovar distribution and various variables
Various demographic, clinical, and behavioural parameters were analysed for a possible association with 
the infecting serogroup. Serogroup distributions within these variables are shown in table 3. For nearly 
all variables the serogroup distribution showed that serogroup B was most prevalent. No signifi cant sero-
group differences were found between symptomatic vs. asymptomatic patients. Remarkably, all 7 females 
in the STD clinic population engaged in prostitution had serovar E. This results in a signifi cant differ-
ence between these women and the STD women not engaged in prostitution for serovar E (p=0.0007). 
Their ethnicity was as follows: two were DC, one was Turkish, three were other European, and one was 
unknown. No other signifi cant differences were found.
Table 3. Demographical, clinical and behavioural parameters in relation to serogroup in two populations (OPD O&G and 
STD clinic). 























Female 37(52.1) 24(33.8) 10(14.1 71 92(51.8) 65(36.7) 20(11.3) 177 - - - -
Male - - - - - - - - 79(46.5) 62(36.5) 29(17.1) 170
-Heterosexual - - - - - - - - 59(48.0) 45(36.6) 19(15.4) 123
-Bisexual - - - - - - - - 3(33.3) 5(55.6) 1(11.1) 9
-Homosexual - - - - - - - - 14(40.0) 12(34.3) 9(25.7) 35
Symptoms
Symptomatic 24(46.2) 19(36.5) 9(17.3) 52 27(52.9) 19(37.3) 5(9.8) 51 29(47.5) 20(32.8) 12(19.7) 61
Asymptomatic 13(68.4) 5(26.3) 1(5.3) 19 57(50.9) 41(36.6) 14(12.5) 112 46(44.7) 40(38.8) 17(16.5) 103
Abdom. pain† 11(55.0) 5(25.0) 4(20.0) 20 12(66.7) 6(33.3) - 18 - - - -
Co-infections* 29(47.5) 25(41.0) 7(11.5) 61 9(37.5) 12(50.0) 3(12.5) 24 15(50.0) 10(33.3) 5(16.7) 30
History STD - - - - 19(54.3) 12(34.3) 4(11.4) 35 15(40.5) 10(27.0) 12(32.4) 37
History CT - - - - 16(51.6) 11(35.5) 4(12.9) 31 9(34.6) 8(30.8) 9(34.6) 26
No partners‡ - - - - 2 [1-8] 1 [0-7] 2 [1-5] 3 [1-25] 3 [0-80] 4 [1-10]
Prostitution - - - - 7(100) - - 7 - - - -
*We combined all co-infections (n) OPD O&G: gonorrhoea (3), syphilis(1), HIV(1), hepatitis B(1), Candida(10), 
Mycoplasma(13), Gardnerella(32); Female STD: gonorrhoea(7), syphilis(-), HIV(1), hepatitis B(2), Candida/bacterial 
vaginosis(14); Male STD: gonorrhoea(10), syphilis(2), HIV(13), hepatitis B(5). 
‡ Median [range].











The percentage of patients in various age-groups in relation to serogroup is shown in fi gure 1. No signifi -
cant differences were found. No age differences were found within the serogroups in the two populations 
(data not shown). The male STD patients were slightly older than the female STD patients (median 26-27 
years of age vs. median 22-23 years of age in all serogroups). Serovar E was the most prevalent serovar in 












Figure 1. Serogroup distribution in different age-groups.
X-axis: age-groups in years; Y-axis: frequency of serogroups (%). B=B-group, I=Intermediate group and C=C-group.
Discussion
This is the fi rst study in the Netherlands taking ethnicity into account inside CT serovar distributions. It 
has been suggested that differences in serovar distribution might be the result of different ethnic compo-
sitions of the population. This suggestion was not confi rmed in the current cohort-based study, since no 
major differences in serovar distributions were observed. 
Questionnaire based ethnicity data were collected, however, mixed ethnic background cannot be 
excluded.
The median age in most ethnic groups were comparable, although the Surinam male STD clinic 
patients were slightly younger than the DC male STD clinic patients. Male DC and NA STD clinic patients 
were signifi cantly older than female DC and NA STD clinic patients. 
The prevalence and age distribution in the general patient population visiting the O&G department 
and the STD outpatient clinic were determined. On average patients visiting the O&G department were 
older than the women visiting the STD outpatient clinic. We determined the prevalence in our OPD O&G 
population, and it was comparable to a previous study21, with an expected higher prevalence in the STD 
population (3.1% vs. 10.7%). We used the STD clinic annual report for their prevalences. The highest 
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prevalences were found in patients from Netherlands Antilles origin, in both populations, as well as in 
male and female patients.
Over time, no signifi cant changes in serovar distribution were observed in the past. Nevertheless, stable 
and clear differences in CT serovars distributions were found previously in different geographical Dutch 
regions19. 
Worldwide serovars D, E, and F are the most prevalent serovars, encounting for approximately 70% 
of the urogenital CT infections5,6. In the current study serovar G/Ga was the third most prevalent serovar 
after E and F, possibly due to a patient bias, since MSM are also included. The predominance of the 
B-group serovars in most studies conducted in different geographic locations and at different times sug-
gests that these serovars have a biological advantage over the other serovars. The overall distribution of 
serovars closely resembles that found in other studies. When we compared our serovar distribution to the 
study of Spaargaren et al. we found only signifi cant differences in the incidence of the most infrequent 
serovars H and I/Ia.
Geisler et al. found an association between serovar Ia and (high-risk) black population in a STD clinic 
population, also described by others20,22,23. The overall serovar distribution in the predominantly black 
population was similar to that reported elsewhere. These racial differences in serovar distribution might 
be due to behavioural, geographical, or biological factors. It has been suggested that one of the reasons 
could be that there is less mixing with partners from a different race (relatively closed populations)20. 
Also intrinsic biological differences among persons of different race or among chlamydial serovars 
could infl uence acquisition, transmission, and duration of infection (host susceptibility or immune 
response)20,24.
In only one other Dutch study serogroup distribution was described between Dutch Caucasians (DC) 
and Surinam patients in a STD clinic population18. They found that, for both men and women, serovars 
F and G/Ga were less common among (high-risk) Surinam patients. Surinam men were more often 
infected with serovar I and E, Surinam women more often with serovar J. We could not confi rm these 
fi ndings. In our study the serovars for Surinam men were 40% in the B-group, 40% in the intermediate 
group, and 20% in the C-group. For Surinam women the serovars were 43.8% in the B-group, 50% in the 
intermediate group, and were 6.3% in the C-group.
In the Netherlands higher prevalences of CT infections are found in Surinam and NA patients25. One 
might compare these high risk groups with high risk black patients. However, in our NA patients the 
prevalence of CT serovars is lowest in the C-group (prevalence serovar I/Ia in NA men 7.7% and in NA 
women 8%).
A previous study on ethnicity in The Hague suggested a different spread in ethnicity, i.e. less DC and 
more Turkish/Moroccan patients21. The previous study showed that 32.3% of the CT positive patients was 
of DC ethnicity, while the current study revealed that 57.2% of the patients had a DC ethnicity. However, 
when we looked at the OPD O&G patients separately, we found 32.3% DC patients. Apparently there are 
more DC patients visiting the STD clinic than patients from other ethnic background. Our ethnic groups 











were smaller than expected, based on the ethnical distribution in the study performed previously, and 
therefore slightly underpowered21. Since one comparisons between DC and Netherlands Antilles patients 
was borderline signifi cant, larger studies might reveal clearer differences.
It is important to take population, and demographical, clinical, and behavioural parameters into account 
for comparison with other studies. We looked at two well defi ned populations and will describe them 
separately, with special attention to serogroup differences and symptoms. 
In the OPD O&G patients we found no signifi cant difference in the serogroup distribution between 
the symptomatic and asymptomatic patients. 
Persson et al. found in an OPD O&G population in Sweden a serogroup distribution similar to our 
study16. They found that symptoms were not associated with any serovar. Lan et al. found an association 
between serovar G and symptomatic infection in OPD O&G patients in the Netherlands26. We found in 
this population the highest prevalence of the intermediate group serovars in the symptomatic patients 
group, but only 3 out of 19 were serovar G/Ga. 
In the female STD clinic population no signifi cant serogroup differences were found. An earlier Dutch 
study showed a different serogroup distribution compared to our study; B-group similar (54.1% vs. 
51.8%), intermediate group lower prevalence (14.8% vs. 36.7%), and C-group higher prevalence (29.6% 
vs. 11.3%)18. There might be an increase of serovar G over time, as found by Suchland et al. in Seattle; (over 
a 9-year period signifi cant increase of serovar G)23. We found a prevalence of serovar G/Ga of 15.3% vs. 
6.7% found by van Duynhoven et al. in 199818. A similar tendency was found by Geisler et al.27.
Others found that serovars F and G (intermediate group) were associated with fewer signs of cervical 
infection. No differences in serovar distribution were found between patients with PID and those with 
lower genital tract infections17. Lower abdominal pain (referring to possible PID) in women was more 
often associated with serovars F (30%) and G (33%) (Intermediate group overall 32%, B-group 6%, and 
C-group 13%; OR 5.1). A similar observation was made for serovar K. Also a tendency was found towards 
fewer clinical signs of cervical infection with serovar F and G (not signifi cant)7,18. Reason could be that 
serovar F produces less signs of cervical infection and is therefore more often unrecognised and may lead 
to upper genital tract infection17. However, van der Laar et al. found no association between infecting 
serovar and clinical signs of cervical or urethral infection in women5. Two other Dutch studies found an 
association between asymptomatic infections and serovar Ia in women6,26. We could not confi rm these 
fi ndings. 
In the male STD clinic populations we found no signifi cant differences. As was found in the female 
STD clinic population the prevalence of the intermediate serogroup seems to increase over time18,27. 
In men studies on specifi c serovar and clinical manifestations are contradictory5,6,18,28.
Age is an important risk factor for CT infections. It is known that the prevalence of CT infections declines 
with increasing age, in an OPD O&G population, as well as in a STD clinic population26. Although 
behavioural factors, such as age at fi rst sexual intercourse, frequency of partner change, and failure to 
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use barrier contraception, clearly are important in contributing to the increased prevalence of chlamydial 
infections in younger women. The number of inclusion forming units (IFUs) in culture has also been 
shown to be higher in younger women20. Higher inclusion counts in younger patients may imply greater 
transmissibility of infection and may be a factor contributing to the very high age-specifi c prevalence of 
CT infection in adolescents. These infections may represent initial encounters with CT in immunologi-
cally naïve individuals, while priori immunity in older individuals may reduce the IFU counts in recurrent 
infection. In addition, if IFU counts decline with increasing duration of infection, older individuals would 
be expected to have lower counts. Eckert et al. found that women have signifi cantly higher IFU counts 
than men, black patients had signifi cantly lower IFU counts than whites, and C-group serovars had 
signifi cantly lower IFU counts than B-group serovars24. Suchland et al. found serovar B, Ia, and mixed 
serovars to be associated with younger age in a Seattle Public Health clinic. Serovar D, F, H, and K were 
associated with older age, serovar G tended to be associated with the oldest patients. C-group serovars 
might be more common in older patients because immunity against the more prevalent B-group serovars 
developed earlier in life23. This is consistent with the fi nding of lower IFUs in C-group serovars and in 
older patients24. In our study serovar E was the most prevalent serovar in all age-groups. In the age-group 
>40, serovar G was evenly present. We could not confi rm the fi ndings that C-group serovars were more 
prevalent in older women (<20=16,7%, 20-29=13,8%, 30-39=12,3%, >40=15,8%). We did fi nd a higher 
prevalence of serovar J in women >40 years of age. 
The serovar distribution in different age-groups showed no signifi cant differences. A similar 
distribution was found by others23. Lan et al. found serovar E to be the most prevalent one (33,3%) in 
asymptomatic women <30 years of age, and serovar F to be the most prevalent one (30%) in OPD O&G 
patients <30 years of age26. 
In general, the differences in the clinical course of infection can be explained by the interaction between 
the host (host factors) and the pathogen (virulence factors). This is an interaction which will be infl u-
enced by environmental factors such as co-infections and the serological responses induced by infection.
Further studies on the differences in clinical course should include analyses of host genetic factors. 
Host variation might play an important role in the development of clinical disease.
In conclusion, this is the fi rst Dutch study taking ethnicity into account and the second largest, study 
on serovar distribution in the Netherlands. No major differences were found between different ethnic 
groups. It did show some clear differences in serovar distribution for serovar H and I/Ia, compared to pre-
viously published Dutch serovar studies. The clinical course of infection does not seem to be infl uenced 
much by the infecting serovar. 
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Chlamydia trachomatis (CT) serovars are divided in three serogroups, namely serogroup B, serogroup I 
(intermediate) and serogroup C, and subsequently into 19 different serovars. Worldwide, serogroup B is 
the most prevalent, followed by serogroup I. Clear differences have been observed in the duration of infec-
tion and growth kinetics between serovars from different serogroups in murine and cell culture models. 
Reasons for these observed differences are bacterial and host related, and are not well understood. 
The aim of this study was to determine the differences in immunoglobulin (Ig) G responses between 
the three serogroups in a group of patients infected with different serovars.
Serovars were assessed from 235 CT positive patients and quantitative IgG responses were deter-
mined. Analyses of variance were used to compare the IgG responses between the three serogroups.
Of the serovars, 46% were B group (with serovar E the most prevalent: 35.3%), 39.6% were I group 
and 14.3% were C group. A highly signifi cant difference in serologic response was shown when compar-
ing the mean IgG concentrations (AU/ml) of patients having serovars in the most prevalent serogroup 
compared to the other serogroups: B= 135, C= 46 and I= 60 (B vs. C and B vs. I, p<0.001) 
In conclusion, the most prevalent serovars generate the highest serologic responses. 
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Introduction
Chlamydia trachomatis (CT) is one of the most common bacterial sexually transmitted diseases (STDs) 
worldwide. In most cases, infected patients undergo an asymptomatic and uneventful course of infection, 
and are thus likely to remain untreated. Untreated CT can give rise to late complications, including pelvic 
infl ammatory disease (PID), ectopic pregnancy, and tubal pathology resulting in tubal factor subfertility1.
Research devoted to the bacterium has provided insight in the structural components of CT. Strains 
of CT are classifi ed into serovars based on nucleotide sequence differences in the omp1 gene, encoding 
the major outer membrane protein (MOMP)2. To date, 19 serovars of CT are known, generally causing 
conjunctival and urogenital infections3. The different serovars are divided in serogroups, based on 
phylogenetic mapping (table 1). 
Table 1: Serovar distribution into serogroups.
Serogroup Serovar
B B, Ba, D, Da, E, L1, L2, L2a
C A, C, H, I, Ia, J, K, L3
I (Intermediate) F, G, Ga
Conventional serotyping involves CT culture and both monocloncal and polycloncal antibodies against 
the MOMP protein. Currently, polymerase chain reaction (PCR)-based techniques allow rapid identifi ca-
tion of different serovars4-6.
Geographical distributions of serovars/serotypes are very similar worldwide, except in small core 
groups (e.g. men-having-sex-with-men (MSM), and small communities)7,8. 
Relations between specifi c serovars and the clinical course of infection have been observed9-11, 
although confl icting data have been reported12-15. Ito et al. demonstrated that serovars D and E (belonging 
to serogroup B) cause the longest duration of infection in a murine model. Furthermore, a comparison of 
the invasiveness of strains D and H demonstrated a much higher frequency of uterine horn infection with 
serovar D16. In addition, they studied the in vitro growth, and elementary body (EB)-associated cytotoxicity 
of CT serovars D and H, in order to identify the above mentioned differences. These differences cor-
relate with virulence variations between these strains in the mouse model of human female genital tract 
infection, and with phenotypic characteristics that could explain human epidemiological data on serovar 
prevalence and levels of shedding during serovar D and H infection. They showed that serovar H EBs were 
signifi cantly more cytotoxic compared with serovar D EBs, which have a longer duration of infection in 
the murine model and are much more prevalent in humans17. The data suggest a relation between the 
different serovars and the serologic responses in the murine model. This relation has not yet been studied 
in humans, but the murine and in vitro data suggest different serologic responses could be observed. 
Different commercial serologic assays to detect IgG against CT are currently available18. Medac Diag-
nostika has recently developed a new CT IgG ELISA kit (Chlamydia trachomatis-IgG-ELISA plus) which 











allows quantitative measurement of IgG levels in serum, enabling to study the relation between host 
serologic responses and specifi c serovars. 




The study included 235 CT-infected patients, who visited either the outpatient department (OPD) of 
Obstetrics and Gynaecology at the MC Haaglanden Clinic, or the STD outpatient clinic in The Hague, 
the Netherlands from January to October 2008. In the Department of Obstetrics and Gynaecology 
clinical samples were obtained from patients visiting the OPD for various reasons including pregnancy, 
discharge, menstrual disorders, subfertility, and contraception. At the STD outpatient clinic reasons 
for visiting were STD-related complaints, partner notifi cation or STD check-up at the client’s request. 
Information was collected about age, gender (STD clinic only, OPD all female), ethnicity, and symptoms 
(i.e. asymptomatic, symptoms, or upper genital tract infection). Serum samples were collected from all 
patients.
CT detection and genotyping
For the detection of CT we used a probe hybridisation assay from urethral and endocervical swabs (PACE 
2 assay, Gen-Probe). Swabs were analysed within 24 hours according to Gen-Probe’s packet insert 
instructions. 
Amplifi cation, detection and genotyping using the CT DT assay
CT detection and genotyping were determined on all samples positive for CT, using the CT-DT detec-
tion and genotyping assay8. The CT-DT amplifi cation, detection and genotyping steps were performed 
according to the manufacturer’s instructions (Labo Biomedical Products BV, the Netherlands). Briefl y, 
fi rst the CT-DT amplifi cation step was performed on extracted DNA to amplify all serovars available 
in GeneBank. Secondly, the CT detection step was performed to confi rm the results detected with the 
PACE 2 assay. The CT detection step detects all serovars, subserovars, and genovariants in GeneBank, 
but cannot differentiate between serovars. Borderline samples were considered positive. Finally, all PCR 
products that were positive with the CT detection step were further analysed with the CT-DT genotyping 
assay. The CT-DT genotyping assay is a reverse hybridization probe line blot (RHA) with a probe for 
the detection of the cryptic plasmid, and probes to detect the three different CT serogroups (B, C, and 
Intermediate) and the different serovars (A, B/Ba, C, D/Da, E, F, G/Ga, H, I/Ia, J, K, L1, L2/L2a, and L3).
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Serology
Determination of IgG levels in serum of all patients was done with ELISA, as described below.
The ELISA procedure using the Chlamydia trachomatis-IgG-ELISA plus kit (Medac Diagnostika), 
was performed according to the manufacturer’s protocols. The assay employed was a quantitative IgG 
serology kit. Calculations to determine concentrations of IgG (Arbitrary Units (AU) /ml) in the serum 
were performed according to the protocols provided. Concentrations below 22 AU/ml were considered 
negative, concentrations between 22 AU/ml and 28 AU/ml were considered equivocal, and concentra-
tions above 28 AU/ml were considered positive, as per the manufacturer’s instructions. 
Statistical analyses
Analysis of variance (ANOVA) statistics were used to compare the IgG serum levels of the three CT 
serogroups. Equivocal values were excluded from these calculations. Analyses were performed with 
GraphPad Instat 3; p values < 0.05 were considered signifi cant: p values between 0.05 and 0.1 were 
considered a statistical trend.
Results 
Serovars
The serovar distribution in the cohort is shown in table 2. Serovar E (35.3%; serogroup B) was the most 
prevalent, followed by serovar F (25.1%) and serovar G/Ga (14.5%; serogroup I) (Table 2). It was found 
that 108 of the samples (46.0%) contained serovars belonging to serogroup B, 93 samples (39.6%) 
belonged to serogroup I, and 34 samples belonged to serogroup C (14.5%). The serovars A, C (both 
ocular serovars), and L1 – L3 were not observed in the studied cohort.
Table 2: Serovar distribution and mean concentrations of IgG per serogroup.
Serogroup Serovar no. of patients % Total patients per 
serogroup
% mean [IgG]*
B B/Ba 2 0.9 108 46.0 134.9
D/Da 23 9.8
E 83 35.3




I F 59 25.1 93 39.6 60.2
G/Ga 34 14.5
235 100% 235 100%
*Mean IgG concentrations in Arbitrary Units per ml (AU/ml), as per manufacturer’s instructions.












Serum CT IgG concentrations were measured for all patients using the Medac Chlamydia trachomatis-IgG-
ELISA plus assay and mean CT IgG levels (AU/ml) were calculated per serogroup, as shown in table 2. 
Serogroup B, containing the most prevalent serovar E, had the highest mean IgG concentration. Highly 
signifi cant differences were observed comparing serogroup B to the other serogroups (B vs. C: p < 0.001; 
B vs. I: p < 0.001), while no statistically signifi cant differences were observed between serogroups C and 
I (C vs. I: p > 0.05).
Discussion
This is the fi rst study to compare serologic IgG responses in urogenital CT infections based on serogroup. 
As expected, serovar E is the most prevalent serovar in our study, followed by serovars F, and G/Ga. The 
mean CT IgG response was signifi cantly the highest in serogroup B (including the most prevalent serovar 
E), compared with the other serogroups. No differences were observed in the mean CT IgG concentra-
tions between serogroups C and I. 
This study clearly shows that serovar E (in the B serogroup) results in the highest serologic responses. 
This result is partly in line with a previous study showing that variable segments of the serovar E MOMP 
induce high serologic responses19. A similar increase in serologic responses to a specifi c serovar (D) has 
recently been described in an Indian population20. Furthermore, Morré et al. have shown that serovar E 
is more frequent in persistent infections compared with resolving infections21. In the study by van der 
Snoek et al. it was shown that rectally L2-infected men had signifi cantly higher serologic titers compared 
with men not infected rectally with lymphogranuloma venereum (LGV)22. The authors concluded that 
these signifi cantly increased titers, which can slowly diminish over time, probably represent the severe, 
more invasive, and more often chronic infl ammation of the rectum caused by LGV serovars, compared 
with other serovars. Murine studies have shown that serovar D results in a longer and more invasive 
infection compared to serovar H, but resulted in less cytotoxicity17. Combining the results from this study 
with the published literature clearly shows that specifi c serovars may elicit stronger serologic responses 
compared with other serovars, and that this might be due to a more aggressive, or invasive course of 
infection. Specifi cally, serovars in the B serogroup (i.e. serovars D, E, and L2) seem to result in more severe 
infections.
These results and those on the toxicity of CT serovars can be combined with data on development 
of complications and symptoms to gain more insight into the immunological responses underlying 
Chlamydia pathogenesis17,23.
In conclusion, the present study demonstrates that serovars of serogroup B induce higher serologic 
responses than serovars of serogroups C and I. The results of this study will be included in a much larger 
EU Framework study to confi rm these results, to further enhance the power of the study, and enable 
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multivariate analyses to obtain further insight in the immunopathogenesis of CT infections. This will 
enable risk profi ling of at-risk patients to prevent development of long-term complications.
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Uterine instrumentation, such as curettage, intrauterine device (IUD) insertion, or hysterosalpingography 
(HSG), may lead to upper genital tract infections in women with Chlamydia trachomatis (CT) infections. 
There are no general policies in the Netherlands with regard to the prevention of complications of CT 
infections as a result of uterine instrumentation. To develop a guideline we determined the prevalence of 
CT infections in a general outpatient department (OPD) of Obstetrics and Gynaecology (O&G), and tried 
to identify risk factors in subpopulations. A second objective was to determine what sample site would be 
most effective in detecting CT infections in women. Further, we studied the distribution of serovars over 
various sample sites. The results of our prospective cohort studies will be discussed in PART I. 
Serum Chlamydia IgG antibody testing (CAT) has been widely introduced in the fertility work-up, as 
a screenings method for tubal pathology. The microimmunofl uorescence assay (MIF) is considered the 
‘gold standard’. However, this assay is very laborious, requires experienced laboratory technician, and 
cross-reactivity may occur. Therefore, new serological assays have been developed. We evaluated two new 
available enzyme immunoassays (EIAs) in various populations. The role of serology will be discussed in 
PART II.
Data about specifi c serovars and the clinical course of infection, the rate of upper genital tract 
progression, and the clearance-persistence rate are inconclusive. We need to get more epidemiological 
information about the CT serovars and serogroups. Therefore, in PART III we focus on the different CT 
serogroups and serovars, both to get insight in the serovar distribution within different ethnical groups, 
and to get insight in the relations between the serological responses and serovars/serogroups.
In addition, recommendations and suggestions for future research are provided.
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Prevalence and risk factors
The overall prevalence of CT infections in our OPD of Obstetrics and Gynaecology was 4.5%, compa-
rable to other European studies1,2. Risk factors, i.e. age and postcoital bleeding, as identifi ed in other 
populations were confi rmed1,3 (Chapter 2). We found signifi cantly higher prevalences in younger women 
(15.8% < 20 years of age and 6.9% < 30 years of age). Approximately 75% of our CT infections occurred 
in women under 30 years of age, and nearly 92% in women under 40 years of age. In the United States 
population screening has been advised for women 15–24 years of age, in other countries age-based 
screening for women under 30 years of age has been advised2,4. We conclude that to prevent complica-
tions of uterine instrumentation it might be useful to screen all women in the fertile age (<40) or give 
prophylactic antibiotics.
Our study confi rms the association between CT infections and postcoital bleeding. However, since all 
patients with the complaint of postcoital bleeding and a CT infection were under 30 years of age, this did 
not help to reveal more CT positive patients than age-based screening alone. We could not confi rm the 
relation between CT infections and ethnic origin as described in other studies, in which a signifi cantly 
higher prevalence was found in women from Suriname and the Netherlands Antilles, although we 
observed a trend in a similar direction5.












The prevalence and risk factors we found were comparable to other studies (European, inner city, OPD 
Obstetrics and Gynaecology population). 
Uterine instrumentation
Risk for upper genital tract infection
Women undergoing uterine instrumentation are at risk for developing upper genital tract infection as a 
result of either ascending cervical infections, or as a result of reactivation of microorganisms persisting 
in the genital tract6. However, there are no randomised controlled trials in which the protective effects of 
prophylactic antibiotics for transcervical intrauterine procedures were studied7. 
Prevalence of pelvic infl ammatory disease (PID) after uterine instrumentation is diffi cult to assess. 
Forseyl et al. describe clinical pelvic infection in up to 4% of the patients after HSG, and in 10% of the 
patients after HSG with tubal disease present6. There is limited information available on complications of 
IUD insertion or abortion curettage. Grimes et al. found after IUD insertion with or without prophylactic 
antibiotics an OR of 0.70 (95% CI 0.36-1.38) in high risk populations, and therefore no signifi cant dif-
ference in subsequent PID8. There are no recent studies and in the older ones usually no differentiation 
between CT PID and PID caused by other bacteria is made. In many studies the criteria for PID are unclear. 
In some studies PID is confi rmed by laparoscopy, while in other studies symptoms of abdominal pain, 
sometimes combined with fever or ultrasound abnormalities are used as criteria for PID.
Especially for women attending fertility clinics the issue of prophylactic antibiotics, or the screen-and-
treat approach prior to uterine instrumentation, is under discussion. Both methods have their pros and 
cons which will be discussed in the following section. Cervical sampling by NAAT (nucleic acid amplifi -
cation test) is a sensitive test to detect CT infections9. IgG antibodies to CT are considered as evidence for 
a past CT infection; however they do not refl ect an actual cervical infection10. Women with CT antibodies 
could be harbouring a (dormant) CT infection, and are therefore at risk for reactivation of the infection. 
The characteristics of the serological assays will be discussed in Part II. Chlamydial heat shock protein 
(cHSP60) antibodies appear to have a high correlation with tubal occlusion11, Chapter 5. However, in women 
without antibodies, the presence of Chlamydia in the upper genital tract can not be excluded. Therefore, 
Land et al. and Thomas et al. suggest that all subfertile women should receive prophylactic antibiotics 
before uterine instrumentation12,13. Ng et al. and Macmillan conclude otherwise14,15. They conclude that 
routine antibiotic prophylaxis may be associated with increased risk of persistent or recurrent infection16, 
and could lead to antibiotic resistance17,18. In case of routine antibiotic prophylaxis there is no screening 
of the partner nor screening for other bacteria, which may cause PID (Mycoplasma, anaerobe and aerobe 
bacteria, and gonorrhoeae). Witkin et al. suggest an alternative approach; both cervical IgA antibodies to 
CT and serum anti-chlamydial HSP60 screening, to provide the best indication as to which women may 
be harbouring CT19. 
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RCOG recommendations
The Royal College of Obstetricians and Gynaecologists (RCOG) recommend in their 1998 guidelines that 
all women undergoing uterine instrumentation should be screened for Chlamydia, or should receive pro-
phylactic antibiotics20. The 2000 guidelines are more ambiguous: screening for Chlamydia prior to uterine 
instrumentation should be considered only in patients at risk, i.e. women <25 years, and protection against 
upper genital tract infections should be considered in all women presenting for fertility investigation21. 
In their 2004 guidelines they state that before undergoing uterine instrumentation women should be 
offered screening for CT using an appropriately sensitive technique, and prophylactic antibiotics should 
be considered before uterine instrumentation if screening has not been carried out22. 
They do recommend antibiotic prophylaxis for termination of pregnancy. 
Screen-and-treat or antibiotic prophylaxis
Penny et al. found screen-and-treat in preventing PID in women undergoing an induced abortion to be 
more cost-effective than prophylactic antibiotics23. Ng et al. and Macmillan made several side marks, 
as mentioned above14,15. We conducted a cost-effectiveness analysis for preventing PID after uterine 
instrumentation in a general O&G population (data not published). It turned out to be very diffi cult to 
establish the prevalence of PID after uterine instrumentation. Prophylactic antibiotics for all seemed 
most cost-effective. We also sent a questionnaire to gynaecologist in the urban areas in the western part 
of the Netherlands in which we asked for the preferred strategy to prevent PID after uterine instrumenta-
tion (fi gure 1). Although the majority considered prophylactic antibiotics for all to be most effective, they 
preferred a screen-and-treat policy in daily practice (data not published). 
Figure 1. Tree for the disease progression with seven strategies to prevent CT PID after uterine instrumentation (© J.Kievit)












In conclusion, policy for prevention of CT PID after uterine instrumentation in (sub)fertile women is still 
subject of debate. We would prefer a screen-and-treat policy, for both a PCR of a cervical sample as well 
as CAT.
Test characteristics and sample sites (summarised in table 1.)
DNA probe or urine analysis 
In our CT prevalence study (Chapter 2) nearly half of the CT infected patients (44%) were detected by 
only one of the two diagnostic tests (DNA probe (cervix, urethra and rectum) or urine analysis). Since no 
discrepant analysis was performed some false positive or negative results cannot be excluded. 
With respect to the sampling site of the DNA probe, we found 70.8% of the CT infected patients to be 
positive on the cervical sampling site. A remarkable high percentage of 12.5% of the CT infected patients 
was found positive at the urethral sampling site only, clearly indicating that sampling the cervical/vaginal 
site only results in a signifi cant number of false negative patients. Multiple site infections were found in 
18.8% of the patients. Six patients were found positive at the rectal sampling site, of which in 3 patients 
this was the only positive site. For women it is advised to test urine or a urethral specimen in combination 
with a cervical specimen24. Other studies found the vaginal introitus also a representative site to detect CT 
infections, with the advantage of being noninvasive25. Rectal swabs should only be obtained in women at 
high risk of being infected. We would have missed three CTI patients if we had used only the cervical swab 
and the urine analysis. These three patients were found positive by anorectal swab only. If we had used 
only the cervical and urethral swab we would have missed 15 CT patients (24.2%) (12 patients (19.4%) 
only positive by urine analysis and three patients only positive by rectal swab with negative urine analysis). 
Sample sites female patients
In our second cohort of OPD O&G population, all patients (n=71) were tested at both the cervical and 
urethral sampling site (Chapter 3). We found 91.5% of the CT infected patients to be positive on the cervi-
cal sampling site, and 8.5% was positive on the urethral sampling site only. Multiple site infections were 
found in 53.5% of these women. These results are similar to our previous results described in Chapter 2. 
Mahto et al. found similar results, 91.1% of the CT infected patients to be diagnosed by cervical swab only, 
and 8.9% to be positive on the urethral site only26. In 85.6% multiple site infections were found.
In all female patients (OPD O&G and STD clinic), cervix or vagina sampling revealed 94.9% of the 
CT infected patients. A questionnaire of the history of sexual behaviour would help to reveal the others 
(rectum and pharynx). 
Sample sites male patients
In male patients, urethral site sampling or urine revealed 85.9% of the CT infected patients. In men-
who-have-sex-with-men (MSM) rectal samples should be taken as well, to detect more patients with a 
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CT infection. In our study all, but one patient were found using these sample sites. In the literature the 
prevalence of rectal CT infections is 8.5% in a MSM population27. In our study, 28 out of 40 patients 
tested at the rectal site were positive for CT (70%). 
The pharyngeal site
The pharyngeal sampling site does not seem to contribute much to the detection of CT infected patients. 
It is not known whether this site has clinical implications, if standard treatment is effective and of the 
infection can be transmitted via oral sex or kissing. We found 11 out of 141 (7.8%) tested female patients 
to be positive at this site, and 6 out of 43 (13.6%) tested male patients. Over 70% of the positive patients 
were positive on other sites too. In only fi ve of the tested patients (2.7%) this was the only positive site The 
same positive rate was found by others (6-18%, in various populations)28,29.
Multiple site testing
The prevalence of multiple site infection in our studies was somewhat lower than described by others 
(table 1). Michel et al. found that over 80% of 73 women tested positive for CT on 4 sample sites (cervix, 
urethra, vaginal secretions and fi rst-void urine (FVU))30. The cervical swab had the highest sensitivity 
(98.6%) (CT organism load), followed by vaginal secretions (94.5%), urethra (93.2%) and FVU (84.9%). 
Vaginal swabs perform better in detecting CT infections than FVU, and nearly as well as cervical swabs, 
but are probably more acceptable than the latter in screening asymptomatic patients since no gynaeco-
logic examination is necessary. In men over 96% of patients was found positive at two sites (urethra and 
FVU), with no signifi cant difference between the CT load, making FVU a more practical and acceptable 
screening method in asymptomatic patients.
Tabel 1. Percentage of CT infected patients found per tested sampling site.
Female Male(m)/Female(f ) Male
Sample sites
Authors
cervix/vagina urethra multiple rectum pharynx urethra/urine multiple




























Matho (ref 26) 91.1% 94.4% 85.6% - -
Ivens (ref 27) 8.5%(m)
Carré (ref 28) 3.8%(f )
1.1%(m)
Hamasuna† (ref 29) 44-61%(f )
6-10%(m)
Michel‡ (ref 30) 80.8% 96.6%
(*) Percentage of tested patients (STD)
† f=female sex worker, m=student
‡ For female patients positive on 4 samples sites, for male patients positive on 2 sample sites.












Although DNA amplifi cation methods used on urine specimen are reported to be so sensitive that they 
may refl ect positivity at the cervical sampling site, our study shows discrepancies. Therefore we conclude 
that, although population screening on CT infected patients with urine analysis is an easy method, cervi-
cal or vaginal specimens are complementary in women. The vaginal samples could also be self-obtained 
if preferred, as well as urine. In men FVU would probably be the best screening method. In both male and 
female patients rectal and/or pharyngeal samples should be obtained if rectal and/or oral sex is reported. 
Serovar
Concurrent serovar infections
Concurrent serovar infections in one sample site are rare. We found prevalence of concurrent serovar 
infections (2.6%) in the same (low) range as described in other studies31. 
Worldwide, serovars D, E, and F are most prevalent31,32. In our study, we found in most sampling sites 
serovar G/Ga to be the third most prevalent serovar after D and E. Recent studies have demonstrated 
an association between CT serovar G and squamous cell carcinoma33. Interestingly, the prevalence of 
serovar G/Ga was the lowest (5.7%) at the cervical sampling site in our study. Similar to our results, Lan et 
al. found serovar G as the third most prevalent serovar in young women visiting an OPD of Obstetrics and 
Gynaecology34. In some Asian countries higher prevalences of serovar G have been observed (7-15%), 
mostly in STD clinic populations, but also in obstetrical and gynaecological patients (14.9%)35.
Rectal versus urogenital serovars 
In men, serovars D/Da and G/Ga were signifi cantly more prevalent in rectal than in urogenital swabs 
(28% vs. 7.9% and 40% vs. 13.6%, p=0.0081 and p=0.0033, respectively), suggesting tissue tropism, still 
based on unknown virulence factors. Also in women these serovars were more prevalent, although not 
signifi cant (33.3% vs. 9.6% and 22.2% vs. 13.8%). In men, serovar E was more prevalent in the urogenital 
swabs than in the rectal swabs (40.7% vs. 8%, p=0.0012), while in women it was approximately the same 
(35.3% vs. 44.4%), and in the normal range as compared to other Dutch studies. In female rectal speci-
mens serovar E was most prevalent. The serovars B/Ba, H, I/Ia, and K were not found in the rectal swabs 
in both men and women. In women serovar J and F were also not found in rectal swabs. 
The same results were found by Barnes et al.36. The rectal swabs were obtained from MSM. They also 
tested the rectal swabs of 32 women and found two serovars B, one I/Ia, and one K. In our study those 
serovars were not found in men or women. It is suggested that these serovars are less viable in the rectum. 
The permeability to toxic substances could be infl uenced by the porin activity of the MOMP, therefore 
serotype might refl ect organism permeability36,37. However, other still unknown virulence factors linked 
to serovars and CT strains in general might be responsible for the differences in sample site and infection 
rates. 
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Two explanations for the prevalence differences between rectal en urogenital specimens, not mutually 
exclusive are present: 1) serovars G/Ga and D/Da have a higher affi nity to epithelial cells of the rectum 
compared to urogenital epithelial cells, potentially partially mediated by the environment and 2) the high 
incidence of serovars G/Ga and D/Da in rectal specimens of MSM fi nds its origin in differences in sexual 
behaviour and group dynamics compared to heterosexuals. However, since in the heterosexual women 
included in our study the same trend was found, serovar distribution linked to core groups is less likely 
as an explanation. Other studies fi nd similar results; most rectal Chlamydia infections were caused by 
serovar G/Ga (47.9%) in MSM, while in the same population the prevalence of urogenital serovar G/
Ga for men and women was much lower (16% vs. 11% resp.)38,39. In San Francisco, rectal specimens of 
MSM were tested in two populations40. The prevalence of CT infections was 8.8% and 5.7% in patients 
visiting a STD clinic or a Gay men’s health centre, respectively. Unfortunately, no serovar analysis was 
performed. Barnes et al. describe signifi cant higher prevalences of serovar G/Ga in cervical isolates of 
heterosexual women and rectal isolates of MSM36. The prevalence of serovar G/Ga (13%) in the rectal 
isolates is however signifi cantly lower than in our study (40%) (p=0.0026). 
Conclusion
In conclusion: the prevalence of multiple serovar infections at different sites of the same individual is 
relative low. Therefore serovar analysis could be performed on one positive sample site. Signifi cant dif-
ferences in serovar distribution are found in rectal specimens of MSM with serovar G/Ga as the most 
prominent, with a same trend in women which did however not reach statistical signifi cance. 
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The role of serology
Chlamydia IgG antibodies
Since many cases of tubal pathology are due to CT infections, serum Chlamydia IgG antibody testing 
(CAT) has been introduced in the fertility work-up, as a screenings method for tubal pathology. Chla-
mydia IgG antibodies remain detectable for years, even after antibiotic treatment, and are therefore a 
marker of a recent or past infection41,42. The microimmunofl uorescence assay (MIF) is considered 
to be the gold standard for the serological diagnosis of CT infections. However, this test has several 
limitations; cross-reactivity with Chlamydia pneumoniae (CP) in the existing assays should be taken into 
account43, MIF is laborious and reading subjective, and therefore, not suitable for daily routine. Recently 
new commercially available species-specifi c (peptide-based) enzyme immunoassays (EIAs) have been 
developed for the detection of CT antibodies. These EIAs provide objective reading and allow handling of 
more samples at the same time. So far they miss clinical evaluation. 
Comparison of serological assays
Prevalence of antibodies (see table 2)
Comparison was made of two new assays, CT-pELISA (Medac, Germany) and BAG-Chlamydia-EIA (Biol-
ogische Analysensystem GmbH, Germany) with MIF as gold standard, in various groups of obstetrical 
and gynaecological patients (patients with subfertility, pregnant women, control group and CT positive 
patients) (Chapter 4). 
The seroprevalence rates of IgG and IgA antibodies (using pELISA) found in our study were compara-
ble to results found by others, except for our subfertility group, in which we found a lower prevalence44-47. 
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A possible explanation for the lower prevalence rate in our subfertility group might be that this group 
included only a small number of patients with tubal factor infertility (TFI) (n=11), where in other studies 
larger numbers of TFI patients were found. Therefore, comparison with non-TFI patients might be more 
applicable. The prevalence rates of CT-IgG-antibodies using the MIF were lower than described in other 
studies43,44,48. However, in other studies the titer at which the MIF is considered positive is often not 
mentioned, or lower. A lower titer will give more ‘false’ positive results.

























IgG 21.1 - 60 33-60 65 31.6 32-58 22-84
IgA 1.3 - 15.3 11-15 28
Pregnant
IgG 17.3 - 12 30 23.3 16
IgA 3.3 - 3 10
Control*
IgG 19.1 35 14.4 14 31.4 39 11
IgA 5 3 6.4 4
CT positive
IgG 65 47 60.5 62.5 74 85
IgA 17.5 - 24.6
* Control group varies in studies: gynaecology patients, blood donors.
Test characteristics (see table 3)
By using the MIF assay as the gold standard, the test characteristics of the Chlamydia-EIA and pELISA 
for the determination of serological evidence of a recent or past CT infection therefore depended on the 
patient group tested. Both tests have reasonably high specifi city and negative predictive value (NPV) and 
would therefore match the criteria of a screening test. We have to consider that cross-reactivity with other 
Chlamydia species may occur as in the MIF assay43,49. Morré et al. compare three ELISAs (including pELISA) 
with MIF as the gold standard44. They conclude that the ELISAs perform as well as the MIF, with the advan-
tage of being less laborious, less expensive and easier to perform. The specifi city and NPV are comparable 
to our results. Sensitivity and PPV in our study were somewhat lower. A possible explanation could be that 
Morré et al. found for their ‘in-house’ MIF assay a titer of ≥ 1:16 diagnostically signifi cant, while we used 
a titer of 1:6444. Both the ‘in-house’ character and different cut-off levels make it hard to compare results. 
We did not fi nd other studies describing the performance of the Chlamydia-EIA. In our study test charac-
teristics for both tests were comparable, although the Chlamydia-EIA had a better sensitivity than pELISA 
and the pELISA a slightly better specifi city than the Chlamydia-EIA.











Table 3. Test characteristics of the Chlamydia-EIA and pELISA in relation to MIF in different groupsa
Chapter 4 Subfertility Pregnant Control Morré (44)





Sensitivity 66.7 58.3 77.1 62.9 76.8 47.8 71.4
Specifi city 84.6 96.2 91.3 96.5 89.4 94 97.3
PPV 66.7 87.5 73 84.6 76.8 78.6 96.2
NPV 84.6 83.3 92.9 89.5 89.4 79.8 78.3
a MIF (IgG) was used as the gold standard.
b For all parameters, values are percentages.
Detection of tubal pathology (see table 4)
When serology is used to detect tubal pathology, high specifi city is important. However, when we used 
tubal pathology as the gold standard, specifi city and NPV are somewhat lower. We have to consider that 
these results are based on a small number of patients (n = 32), and even a smaller number of patients with 
tubal pathology (n = 11). Further, in our study we evaluated tubal pathology by reviewing the laparoscopy 
report. In 33% of patients with patent tubes, CT IgG antibodies were found by one or more assays, and 
in 27% of patients with tubal pathology no CT IgG antibodies were found by any of the assays. The lat-
ter could be explained by other causes of tubal pathology. Further, not in all patients CT antibodies are 
formed. It is clear that no assay can predict the presence of tubal pathology with a very high sensitivity 
and specifi city.
Gijsen et al. described no signifi cant differences between two peptide-based EIAs and the MIF in 
predicting tubal pathology50. Our test results were comparable with theirs, with the exception of the 
pELISA, which showed a lower sensitivity but higher specifi city. 
Land et al. compared CAT and tubal pathology at laparoscopy, using fi ve serological tests51. They 
found a better NPV for the MIF (93%) (using the same titer as we did, 1:64) and pELISA (91%). Mouton 
et al. found a similar NPV (as Land et al.) for the pELISA (93%)52. A stricter use of defi nition for tubal 
pathology might be an explanation for different results. Land et al. suggested cross-reactivity with CP for 
all CAT tests, except pELISA. Verkooyen et al. however, found no suggestion for cross-reactions with CP53.
Again, the use of different cut-off levels and different defi nitions of tubal pathology have to be taken 
into account. In the Netherlands tubal pathology is often defi ned as extensive peri-adnexal adhesions 
Table 4. Test characteristics of the Chlamydia-EIA, pELISA and MIF in relation to tubal pathology (IgG).










Sensitivity 54.6 36.4 63.6 61 71 55 66.7
Specifi city 71.4 85.7 81 68 74 87 75
PPV 50 57.1 63.6 LR+ 1.9 35 45 30.3
NPV 75 72 81 LR- 0.6 93 91 93.2
a For all parameters, values are percentages.
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and/or distal occlusion of at least one tube. While in Finland the severity of tubal damage is described 
following the classifi cation of Hull and Rutherford. The appropriate cut-off level (number of false posi-
tive or false negative results) depends on patient characteristics, the available facilities and costs. CAT 
does seem more accurate in predicting severe distal tubal pathology than unspecifi ed tuboperitoneal 
abnormalities54. 
Conclusion
A screening test needs high specifi city and a high NPV. pELISA seems to be a good alternative for MIF for 
the detection of CT antibodies. pELISA is more species-specifi c than the Chlamydia-EIA. It is less labori-
ous and less expensive than MIF. When the pELISA and Chlamydia-EIA are compared with MIF as the 
gold standard, pELISA has the highest specifi city, and in the subfertility group, it has an NPV comparable 
to that of Chlamydia-EIA. A higher NPV would help to better eliminate patients without tubal pathology. 
Chlamydia IgA antibodies
For CP IgA antibodies have been associated with chronic infl ammation and persistent infection55,56. The 
prevalence of IgA antibodies in the CT negative patients in our study were comparable to those found in 
blood donors, but the prevalence in CT positive patients we found was lower than found by Verkooyen 
et al. (pELISA: 17.5 vs. 45%, respectively)53. Again, differences in defi nition of tubal pathology could 
explain this. Signifi cantly more CT IgA antibodies were found in women with tubal pathology, compared 
to women without tubal pathology52,57. However, the OR of IgA antibodies was signifi cantly lower than 
the OR of IgG antibodies to CT (6.1 vs. 13.9, resp.)57. Mouton et al. however, found for IgA antibodies a 
higher PPV for tubal pathology compared to IgG antibodies (pELISA: 47.1% vs. 30.3%, respectively)52. 
Conclusion
The role of IgA antibodies in the serodiagnosis of CT with the currently available assays remains further 
to be determined.
Chlamydia HSP60 antibodies
IgG antibodies to Chlamydia heat shock protein 60 (cHSP60) have been suggested as markers of chronic 
infl ammation, and may therefore be good predictors of tubal pathology. These antibodies were found in 
over 70% of women with occluded tubes and in <20% of women with patent tubes58. Results of many 
studies are based on ‘in-house’ assays, which lack standardisation. Although comparison of the differ-
ent ‘in-house’ assays is diffi cult, there is consensus that the anti-cHSP60 responses in women increase 
with the severity of CT associated disease58,59. Due to the signifi cance of the possible association of 
the response to cHSP60 and progressive disease, a commercially produced assay that employs defi ned 











cHSP60 epitopes should allow for the comparison of results obtained in different laboratories, as well as 
forward the use of cHSP60 as a diagnostic tool, if the assay proves to be relevant in predicting pathology 
or clinical outcome of a urogenital chlamydial infection. 
Seroprevalences in women with different degrees of tubal pathology
We evaluate a recently introduced commercially available cHSP60 serologic assay and determined the 
anti-cHSP60 responses in three groups women (Chapter 5). This is the fi rst study evaluating the commer-
cially available cHSP60 assay in women with different degrees of tubal pathology (1. women with patent 
tubes, 2. pregnant women and 3. women with tubal pathology). We found the expected clear difference 
in IgG seroprevalence between women with and without (procedure confi rmed) tubal pathology, while 
an intermediate prevalence was observed in pregnant women. The same pattern but with lesser incidence 
was observed in the anti-cHSP60 responses. Finally, the median cHSP60 titers increased from group 1-3: 
50, 100 and 200, respectively, suggesting an association between the level of cHSP60 response and tubal 
pathology.
Petersen et al. and Clad et al. found cHSP60 antibodies in women with pelvic infl ammatory disease (85% 
in patients with CT positive swabs and patients with occluded tubes, 20% in blood donors) and in subfer-
tile women with open or occluded fallopian tubes (31% and 70% respectively)60, 61.
The standardisation provided through this new commercially available assay will potentially enhance the 
comparability of cHSP60 results between laboratories. The results presented here, although obtained in 
small but well defi ned groups, look promising. Indeed, power calculations (alpha =0.5, beta=0.1) show 
that doubling (1.7 times) the size of the (sub)groups would results in signifi cant p values instead of clear 
trends. Den Hartog et al. found a seroprevalence of cHSP antibodies of 15% (n=38) in women without 
tubal pathology and of 50.8% (n=30) in women with tubal pathology57. However, the OR of cHSP60 IgG 
antibodies was signifi cantly lower than the OR of CT IgG antibodies (5.9 vs. 13.9). Cross-reactivity with 
the very similar and highly present CP HSP60 is considered to be the reason for false positive results. 
Conclusion
In conclusion, new commercially available EIAs, including cHSP60 assays, are good alternatives for the 
laborious ‘gold standard’ MIF. The concordance between CT IgG and cHSP60 positivity is high, almost 
90%. An association between the level of cHSP60 response and tubal pathology has been suggested. 
However, further studies are needed in larger groups with different degrees of CT infection induced tubal 
pathology to further determine the diagnostic, prognostic, and clinical relevance of this new assay. 
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The role of serology
Overall, differences in cut-off levels, differences in assays, differences in the defi nition of tubal pathology 
and different patients groups make it diffi cult to compare results.
Laparoscopy is considered the best test to diagnose tubal pathology, and it is the reference test in the 
evaluation of the diagnostic performance of other tests. However, it not suitable as a screenings test. For 
a long time, hysterosalpingography (HSG) has been the screenings test for tubal patency. Compared to 
laparoscopy, HSG has a specifi city of 83%, and sensitivity of 65%62. For CAT to be used as a screenings 
test for tubal pathology it needs high specifi city and high NPV. Recently, CAT has shown to perform just 
as well as HSG in predicting tubal factor infertility63-65. One of the limitations of CAT is the number of 
false positive results for the identifi cation of tubal pathology, which is refl ected in the low PPV. In those 
patients laparoscopies would be performed in the absence of tubal pathology. Cross-reactivity with the 
prevalent CP is generally considered a cause43,51. The prevalence of CP antibodies in subfertile women 
with and without distal tubal pathology is over 70%43,66. However, despite the similarities between CT 
and CP, CP does not seem to contribute to the development of tubal pathology66.
CAT is not useful in discriminating between clearance and persistence of CT infections. And per-
sistence is an important risk factor for tubal pathology. Serological markers for persistent infection, i.e. 
CT IgA, cHSP60 and high-sensitivity C-reactive protein (hs-CRP), were signifi cantly more prevalent in 
women with tubal pathology57. As described before, CT IgA antibodies and cHSP60, do not always seem 
to perform superior to CAT. Combining CAT and hs-CRP, seems promising in identifying women with 
the highest risk of tubal pathology57,67. The combination of tests for humoral and cell-mediated immune 
response could also help to improve the tubal factor infertility prediction model68. 
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Serovar distribution
Currently, 19 different CT serovars and in addition many serovariants have been identifi ed by sero- and 
genotyping69,70. The serovars can be divided into three serogroups: the B-group (serovars B, Ba, D, Da, E, 
L1, L2, L2a), the intermediate group (serovars F, G, Ga) and the C-group (serovars I, Ia, J, K, C, A, H, L3). 
The most prevalent CT strains worldwide are serovars D, E and F. They account for approximately 
70% of the typed urogenital serovars. Conjunctivitis is mainly caused by serovars A-C. In urogenital 
infections serovars D-K are predominantly isolated. Serovars L1-L3 can be found in the inguinal lymph 
nodes31,32,71,72. 
Epidemiology
An increasing number of isolates are typed worldwide and provide a wealth of information on the epide-
miology of CT infections. Several studies have described inconclusive data about specifi c serovars and the 
clinical course of infection, the rate of upper genital tract progression, and the clearance-persistence rate.
Information about the differences in serovar distribution could give information about the epide-
miology of CT infections and might have clinical implications31,36,71,73-75. There is a clear difference in 
the treatment of a Lymphogranuloma venereum (LGV) infection or a CT infection with serovar D-K. 
Further, since 2003 serovariant L2b has been found, which has to be tested specifi cally with a recently 
developed new assay76. Therefore serovar determination could be clinically relevant. A recent study about 
serovar distribution in the Netherlands showed no signifi cant serovar distribution shift over time, but 
geographical differences were observed. This could be the result of different ethnic composition of the 
population77,78. 
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Therefore, we determined the CT serovar distribution among different ethnic populations in the region 
The Hague in two well defi ned cohorts and compared the results to previous obtained Dutch serovars 
distribution studies (Chapter 6). In this study we determined for the fi rst time whether the geographical 
serovar distribution differences are ethnic-based. This study will obtain relevant epidemiological data on 
CT serovars distributions.
Ethnicity
The overall distribution of serovars we found closely resembles that of found in other studies in the 
Netherlands. Worldwide serovars D, E and F are most prevalent31,32. In our study serovar G/Ga was the 
third most prevalent serovar after E and F. The predominance of the B-group serovars in most studies 
conducted in different geographic locations and at different times suggests that these serovars have a 
biological advantage over the other serovars. When we compared our serovar distribution to the study of 
Spaargaren et al. we found signifi cant differences in serovar H and I/Ia. 
Geisler et al. found an association between serovar Ia and black race in a STD clinic population79. 
The overall serovar distribution in the predominantly black population was similar to that reported 
elsewhere. But serovar Ia was only found in a (high-risk) black population, an association also found 
by others78,80. These racial differences in serovar distribution might be due to behavioural, geographical 
or biological factors. It has been suggested that one of the reasons could be that there is less mixing 
with partners from a different race (relatively closed populations)78. And geographic distribution could 
infl uence the distribution of serovar Ia. Also intrinsic biological differences among persons of different 
race or among chlamydial serovars could infl uence acquisition, transmission and duration of infection 
(host susceptibility or immune response)39,78. 
In only one other Dutch study serogroup distribution was described between Dutch Caucasian (DC) 
and Surinam patients in a STD clinic population75. They found that, for both men and women, serovars 
F and G/Ga were less common among (high-risk) Surinam patients. Surinam men were more often 
infected with serovar I and E, Surinam women more often with serovar J. We could not confi rm these 
fi ndings. In our study the serovars for Surinam men were 40% in the B-group, 40% in the intermediate 
group, and 20% in the C-group. For Surinam women the serovars were 43.8% in the B-group, 50% in the 
intermediate group, and were 6.3% in the C-group (1 serovar J).
In the Netherlands higher prevalences of CT infections are found in Surinam and Netherlands Antilles 
(NA) patients5. One might compare these high risk groups with high risk black patients. However, also 
in our NA patients the prevalence of CT serovars is lowest in the C-group (prevalence serovar I/Ia in NA 
men 7.7% and in NA women 8%).
A previous study on ethnicity in The Hague suggested a different spreading in ethnicity, i.e. less DC 
and more Turkish/Moroccan patients81. Our ethnic groups were smaller than expected and therefore 
slightly underpowered. Our power analysis was based in the fi rst cohort. However, compared to our fi rst 
cohort we included less non-DC patients. Since one comparison between DC and Netherlands Antilles 
patients was borderline signifi cant, larger studies might reveal clearer differences.












To make comparisons with other studies concerning demographic, clinical and behavioural parameters 
it is important to take the population into account. We looked at 2 well defi ned populations and will 
describe them separately. 
OPD Obstetrics and Gynaecology
In the OPD O&G patients we found no signifi cant difference in the serogroup distribution between 
symptomatic and asymptomatic patients. 
Persson et al. found in an OPD O&G population in Sweden a serogroup distribution compared to our 
study73. They found that symptoms were not associated with any serovar. Lan et al. found an association 
between serovar G and symptomatic infection in OPD O&G patients in the Netherlands34. We found the 
highest prevalence in the intermediate group for symptomatic patients, but only 3 out of 19 were serovar 
G/Ga. 
Female STD clinic population
In the female STD clinic population no signifi cant differences were found. An earlier Dutch study showed 
a different serogroup distribution compared to our study; B-group similar (54.1% vs. 51.8%), intermedi-
ate group lower prevalence (14.8% vs. 36.7%), and C-group higher prevalence (29.6% vs. 11.3%)75. There 
might be an increase of serovar G over time, as found by Suchland et al. in Seattle (over a 9-year period 
signifi cant increase of serovar G)80. We found a prevalence of serovar G/Ga of 15.3% vs. 6.7% found by 
van Duynhoven et al. in 199875. A similar tendency was found by Geisler et al.82.
Others found that serovars F and G (intermediate group) were associated with fewer signs of cervical 
infection. No differences in serovar distribution were found between patients with PID and those with 
lower genital tract infections74. Lower abdominal pain (referring to possible PID) in women was more 
often associated with serovars F (30%) and G (33%) (Intermediate group overall 32%, B-group 6% and 
C-group 13%; OR 5.1). A similar observation was made for serovar K. Also a tendency was found towards 
fewer clinical signs of cervical infection with serovar F and G (not signifi cant)71,75. Reason could be that 
serovar F produces less signs of cervical infection and is therefore more often unrecognised and may lead 
to upper genital tract infection74.
However, van der Laar et al. found in women no association between infecting serovar and clinical 
signs of cervical or urethral infection31. Two other Dutch studies found for women an association between 
asymptomatic infections and serovar Ia32,34. We could not confi rm these fi ndings. 
Male STD clinic population
For the male STD clinic populations we found no signifi cant differences. As was found in the female STD 
clinic population the prevalence of the intermediate serogroup seems to increase over time75,82. In men 
studies on specifi c serovar and clinical manifestations are contradictory31,32,75,83. 
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Age
Age is an important risk factor for CT infections. It is known that the prevalence of CT infections declines 
with increasing age, in an OPD O&G population, as well as in a STD clinic population34. Although 
behavioural factors, such as age at fi rst sexual intercourse, frequency of partner change, and failure to 
use barrier contraception, clearly are important in contributing to the increased prevalence of chlamydial 
infections in younger women. The number of inclusion forming units (IFUs) in culture also has been 
shown to be higher in younger women78. Higher inclusion counts in younger patients may imply greater 
transmissibility of infection and may be a factor contributing to the very high age-specifi c prevalence of 
CT infection in adolescents. These infections may represent initial encounters with CT in immunologi-
cally naïve individuals, while priori immunity in older individuals may reduce the IFU counts in recurrent 
infection. In addition, if IFU counts decline with increasing duration of infection, older individuals 
would be expected to have lower counts. Eckert et al. found that women have signifi cantly higher IFU 
counts than men, black patients had signifi cantly lower IFU counts than whites, and C-group serovars 
had signifi cantly lower IFU counts than B-group serovars39. Suchland et al. found in Seattle, Public 
Health clinic, serovar B, Ia and mixed serovars to be associated with younger age. Serovar D, F, H and K 
were associated with older age, serovar G tended to be the associated with the oldest patients. C-group 
serovars might be more common in older patients because immunity against the more prevalent B-group 
serovars developed earlier in life80. This is consistent with the fi nding of lower IFUs in C-group serovars 
and in older patients39. In our study serovar E was the most prevalent serovar in all age-groups. In the 
age-group >40, serovar G was evenly present. We could not confi rm the fi ndings that C-group serovars 
were more prevalent in older women (<20=16.7%, 20-29=13.8%, 30-39=12.3%, >40=15.8%). We did fi nd 
a higher prevalence of serovar J in women >40 years of age. 
The serovar distribution in different age-groups showed no signifi cant differences. A similar distribu-
tion was found by others80. Lan et al. found in asymptomatic women <30 years of age serovar E to be the 
most prevalent one (33.3%), and in OPD O&G patients <30 years of age serovar F to be the most prevalent 
one (30%)34. 
Conclusion
In conclusion, this is the fi rst Dutch study taking ethnicity into account and the second largest study 
on serovar distribution in the Netherlands. No major differences were found between different ethnic 
groups. It did show clear differences in serovar distribution compared to previously published Dutch 
serovar studies. The clinical course of infection does not seem to be infl uenced much by the infecting 
serovar. Further studies on differences in clinical course should include analyses of genetic host factors. 
Host variation might play an important role in the development of clinical disease.












Relations between specifi c serovars and the clinical course of infection have been observed, although 
confl icting data have been reported, as we have described before37,71,74,83-86. Ito et al. demonstrated 
that serovars D and E (belonging to serogroup B) cause the longest duration of infection in a murine 
model. Furthermore, a comparison of the invasiveness of strains D and H demonstrated a much higher 
frequency of uterine horn infection with serovar D87. In addition, they studied the in vitro growth, and 
elementary body (EB)-associated cytotoxicity of CT serovars D and H, in order to identify the above 
mentioned differences. These differences correlate with virulence variations between these strains in the 
mouse model of human female genital tract infection, and with phenotypic characteristics that could 
explain human epidemiological data on serovar prevalence and levels of shedding during serovar D and 
H infection. They showed that serovar H EBs were signifi cantly more cytotoxic compared with serovar 
D EBs, which have a longer duration of infection in the murine model and are much more prevalent in 
humans 88. The data suggest a relation between the different serovars and the serologic responses in the 
murine model. This relation has not yet been studied in humans, but the murine and in vitro data suggest 
different serologic responses could be observed. 
Different commercial serologic assays to detect IgG against CT are currently available 44. Medac 
Diagnostika has recently developed a new CT IgG ELISA kit (Chlamydia trachomatis-IgG-ELISA plus) which 
allows quantitative measurement of IgG levels in serum, enabling to study the relation between host 
serologic responses and specifi c serovars. 
IgG responses in different serogroups
We compared serologic IgG responses in urogenital CT infections based on serogroup (Chapter 7). The 
mean CT IgG response was signifi cantly the highest in serogroup B (including the most prevalent serovar 
E), compared with the other serogroups. No differences were observed in the mean CT IgG concentra-
tions between serogroups C and I. This study clearly shows that serovar E (in the B serogroup) results in 
the highest serologic responses. This result is partly in line with a previous study showing that variable 
segments of the serovar E MOMP induce high serologic responses89. A similar increase in serologic 
responses to a specifi c serovar (D) has recently been described in an Indian population90. Furthermore, 
Morré et al. have shown that serovar E is more frequent in persistent infections compared with resolving 
infections91. In the study by van der Snoek et al. it was shown that rectally L2-infected men had signifi cantly 
higher serologic titers compared with men not infected rectally with LGV92. The authors concluded that 
these signifi cantly increased titers, which can slowly diminish over time, probably represent the severe, 
more invasive and more often chronic infl ammation of the rectum caused by LGV serovars, compared 
with other serovars. Murine studies have shown that serovar D results in a longer and more invasive 
infection compared to serovar H, but resulted in less cytotoxicity88. Combining the results from this study 
with the published literature clearly shows that specifi c serovars may elicit stronger serologic responses 
compared with other serovars, and that this might be due to a more aggressive, or invasive course of 
infection. Specifi cally, serovars in the B serogroup (i.e., serovars D, E and L2) seem to result in more severe 
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infections. LGV infections have a more invasive character and therefore a stronger serological response. 
These results and those on the toxicity of CT serovars33,88 can be combined with data on development of 
complications and symptoms in order to gain more insight into the immunological responses underlying 
Chlamydia pathogenesis.
Conclusion
In conclusion, the present study demonstrates that serovars of serogroup B induce higher serologic 
responses than serovars of serogroups C and I. The results of this study will be included in a much larger 
European Union Framework study to confi rm these results, to further enhance the power of the study, 
and enable multivariate analyses to obtain further insight into the immunopathogenesis of CT infections. 
This will enable risk profi ling of at-risk patients to prevent development of long-term complications. 











Recommendations and suggestions for future research
CT infection is the most prevalent sexually transmitted disease, which is strongly associated with PID, 
ectopic pregnancy and tubal factor subfertility. Prevalences are increasing worldwide with almost 100 
million new infections each year. 
Striking differences between individuals have been observed in the clinical course of infection with 
CT. In the case of sexually transmitted infection with CT the following differences have been observed: 
i) transmission versus no transmission; ii) symptomatic versus asymptomatic course of infection; iii) 
persistence versus clearance of infection; and iv) development of late complications (e.g. tubal factor sub-
fertility) versus no development of late complications. However, only a small portion of women develop 
secondary complications after infection.
In general, the differences in the clinical course of infection can be explained by the interaction between 
the host (host factors) and the pathogen (virulence factors). This is an interaction which will be infl u-
enced by environmental factors such as co-infections (see fi gure 2) and the serological responses induced 
by infection.
Figure 2. Integrated research approach for Chlamydia trachomatis infections as based on the clear differences in the 
clinical course of infection observed between individuals93,94.
Clinical recommendations
Young age, complaints of contact bleeding, being of Surinam or Netherlands Antilles origin, and living 
in urban areas are important risk factors for CT infections in the Netherlands95. Intrauterine instru-
mentation could lead to upper genital tract infection if an infection is present. However, it turned out 
to be diffi cult to predict the increased risk of intrauterine instrumentation on the development of PID. 
Whether screen-and-treat or antibiotic prophylaxis for all is the best policy remains therefore still subject 
of debate, and the decision which policy to follow will remain up to the physician. 
However, we advise that when intrauterine instrumentation is performed one should screen for CT 
infections in women in their fertile years (both by PCR and CAT).
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In women, taking cervical swabs and urine analysis were complementary. In a gynaecologic population, 
in which a gynaecologic examination is performed in most patients, taking cervical swabs would give the 
most accurate information (with regard to the intrauterine instrumentation), without extra effort. How-
ever, for screening purposes urine analysis alone of self-taken vaginal swabs may be more acceptable. 
Since the prevalence of multiple serovar infections is relatively low, serovar analysis could be per-
formed on one positive sample site.
CT serovars and strains
In the Chapters 1 and 2 we described the demographic en epidemiological data in a O&G outpatient 
and STD population, while in Chapters 4, 5 and 7 we assessed serological responses to infection and 
its use for diagnostic and prognostic purposes in relation to susceptibility to and severity of infection. 
Besides obtaining new insight in the prevalence in our study groups our fi ndings on sample site specifi c 
serovar distributions, potentially tissue tropism, is of major interest. Future research should focus on 
fi rst reproducing these results in a larger cohort and secondly if the fi ndings will be confi rmed research 
looking more into the biological and molecular background should be initiated to identify the factors 
responsible for this proposed tissue tropism. In the Chapters 3, 6 and 7 we focussed specifi cally on the 
microbial factors, mainly the different strains, called serovars of CT. Serovar typing is used for epide-
miological studies and transmission studies, but is also of clinical relevance for instance in identifying 
the specifi c serovar in rectal infections as LGV types versus other types, as the LGV types need a 3 week 
doxycycline instead on a one time azithromycin. Besides the tissue tropism and general epidemiological 
distribution of serovars identifi ed in the studied populations, we showed for the fi rst time a relation 
between serovars and serological responses mimicking perfectly the incidence of the serogroups in the 
populations worldwide. We are currently already extending these studies to confi rm the results obtained. 
Further future research should focus at the virulence factors responsible. This will mean we have to look 
beyond the ompA gene which defi nes the serovars. Very recently, Multi Locus Sequence Typing (MLST) a 
technique in general used for phylogenetic analyses96 based on co-called housekeeping genes, has been 
adapted focussing on CT 6 genes97 with high variability, so we can look beyond the serovar level to strain 
variation. The fi rst results show this technique identifi es already 3-5 times more strains that typing on 
ompA only. The ultimate approach is sequencing the complete genome of 1Mb from CT for many different 
strains and serovars to identify on a genome level which genes are linked to tissue tropism, virulence, 
upper genital progression, persistence and many other factors of interest, to further unravel the differ-
ences in the clinical course of infection. 
Host genetics
In this thesis 2 of the 3 factors infl uencing the clinical course have been studied, the third, host factors 
(see fi gure 2) were not addressed but are of major interest and importance in the course of infections. 
Since the cellular immune response to CT is subject to genetic infl uences, the degree and mechanisms of 
such genetic control will have important implications in understanding the immunopathogenesis of CT 
infection. Deeper knowledge in these areas will lead to therapeutic strategies and vaccine development. 











Chlamydia twin studies published by Bailey et al. 98 describe the most relevant study in the fi eld of Chla-
mydia immunogenetics. They estimated the relative contribution of host genetics to the total variation 
in lymphoproliferative responses to CT antigen by analysing these responses in 64 Gambian twin pairs 
from trachoma-endemic areas. Proliferative responses to serovar A elementary body (EB) antigens were 
found to be stronger in monozygotic twins than in dizygotic twin pairs. Based on these observations, 
they calculated a heritability of 0.39, thus suggesting that host genetic factors contribute to almost 40% 
of the clinical presentation.
Serology
There seems to be more and more evidence that Chlamydia antibody testing (CAT) can replace HSG in 
predicting tubal factor subfertility. Laparoscopy remains the gold standard. However, CAT can help to 
identify those patients in which a laparoscopy is indicated. Serological markers for persistent infection, 
i.e. CT IgA, cHSP60 and high-sensitivity C-reactive protein (hs-CRP), are more prevalent in women with 
tubal pathology. Especially the combination of CAT and hs-CRP needs further exploration, but seems 
promising in identifying women at high risk of tubal pathology. The combination of test for humoral 
and cell-mediated immune response could help to improve the tubal factor subfertility prediction model.
We were the fi rst to compare serologic IgG responses in urogenital CT infections based on serogroup. 
Our study demonstrates that serovars of serogroup B induce higher serologic responses than serovars of 
serogroups C and I. The results of this study will be included in a much larger European Union Frame-
work99 study to confi rm these results, to further enhance the power of the study, and enable multivariate 
analyses to obtain further insight into the immunopathogenesis of CT infections. This will enable risk 
profi ling of at-risk patients to prevent development of long-term complications.
Integration of all results
Integration of the three lines in fi gure 2 is needed on an international level. The European Union funded 
EpiGenChlamydia Consortium (www.EpiGenChlamydia.EU) 99 aims to structure such transnational 
research to such a degree that comparative genomics and genetic epidemiology can be performed in 
large numbers of unrelated individuals. Biobanking and data-warehouse building are the most central 
deliverables of the Coordination Action of the Consortium in Functional Genomics Research. In addi-
tion, the collective synergy acquired in this Coordination Action will allow for the generation of scientifi c 
knowledge on the CT–host interaction, knowledge on the genetic predisposition to CT infection and the 
development of tools for early detection of a predisposition to CT infection and its complications.
Implementing strategies to promote a faster path for genetic knowledge from bench to bedside will be 
needed in the future. The various stakeholders in public health play a key role in translating the implica-
tions of genomics such as deriving from molecular epidemiology and host-pathogen genomics. This 
knowledge will not only enable clinical interventions but also health promotion messages and disease 
prevention programs to be targeted at susceptible individuals as well as subgroups of the population 
based on their genomic profi le (personalised healthcare). The fi eld involved in this translation is called 
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Public Health Genomics100,101 which has as major task “the responsible and effective translation of genome-based 
knowledge and technologies into public policy and health services for the benefi t of population health” (Bellagio state-
ment, 2005: see www.graphint.org for details).
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Summary
In search of epidemiological risk factors for Chlamydia trachomatis (CT) and prevention of tubal pathology 
we performed two prospective-cohort studies. The results are presented in this thesis. The fi rst study was 
reported in 2002-2004 using a well defi ned cohort of patients visiting an outpatient department (OPD) 
of Obstetrics and Gynaecology (O&G) located in the central urban area of The Hague, and describes the 
epidemiological data of patients with CT infections. 
In the same population we compared two different serological assays for detection of CT antibodies, 
and evaluated the characteristics of a newly developed assay detecting heat shock protein 60 (HSP60) 
antibodies and its role in predicting tubal pathology.
In 2007 a second, sequential study was started at the same OPD of O&G and at the nearby regional 
sexually transmitted disease clinic to fi nalise some of the objectives of our study.
CT infection is the most prevalent sexual transmitted disease in the Netherlands and worldwide. In the 
Netherlands some 60.000 people are infected each year of which 35.000 are women. In women approxi-
mately 70% of the infections are asymptomatic. However, infections caused by CT may lead to serious 
complications such as pelvic infl ammatory disease (PID). Damage to the tubes may result in (tubal factor) 
subfertility and ectopic pregnancy. Infections in pregnant women may lead to neonatal conjunctivitis and 
pneumonia. The highest prevalence is found in young women, who are especially at risk for complica-
tions. It is unknown why some women have asymptomatic infections and others develop symptomatic 
upper genital tract infections. It has been suggested that different serovars and/or host-factors may be 
involved in the clinical course of infection, the rate of upper genital tract progression, and the clearance 
or persistence of infection. 
Treatment of CT infections is simple and effective and when given in time can prevent late complica-
tions. With the development of techniques to detect CT in urine samples screening programs became 
possible and large scale screening programs for asymptomatic infections have been performed.
Uterine instrumentation such as intrauterine device (IUD) insertions, hysterosalpingography (HSG) 
and abortion curettage may cause upper genital tract infection if an asymptomatic cervical infection is 
present, by ascending infection or by reactivation of viable microorganisms in the upper genital tract. 
Therefore, in a population of obstetrical and gynaecological patients it is important to determine risk 
factors for infection
To optimise prevention strategies of such complications we wanted to use these risk factors for CT 
infections in our obstetrical and gynaecological population. Little is known about the dynamics of CT 
serovars and their specifi c role in pathogenicity. Insight in changes of serovar distribution in different 
ethnic groups over time, in relation to clinical data, could explain changes in the epidemiology of CT 
infections and have clinical implications. 
CHAPTER 1 outlines the pathogenesis, clinical course and detection methods of CT infections and 
describes the aims of this thesis.











Part I Clinical characteristics
In CHAPTER 2 we describe the prevalence and risk factors of CT infections in a general OPD of Obstetrics 
and Gynaecology in the Netherlands. 
Age was the most important risk factor in our population (overall prevalence of CT infections 4.5%, in 
women under 20 years of age 15.8%). Another risk factor we found was post coital bleeding. We could not 
confi rm signifi cant differences between women from different ethnic origin or between women using 
different kinds of contraceptives. 
Twelve (19.4%) patients with CT infections were found positive by urine test only, and 15 (24.2%) only 
by DNA probe. In our cohort the analyses of urine and of cervical specimens are complementary for the 
determination of the prevalence of CT infections in women. 
A guideline for the preventive use of antibiotics in uterine instrumentation needs a cost effectiveness 
analysis to assess the tools of age based screening and/or antibiotic prophylaxis. 
In CHAPTER 3 we take another look at the sampling sites and also take the infecting serovar into con-
sideration. 
The aims of the study were to determine the incidence of concurrent infections on serovar level, to 
determine the incidence of multiple anatomical infected sites on CT detection and serovar level, and 
analysis of site specifi c serovar distribution, to identify tissue tropism, with special attention to serovar 
G/Ga for urogenital vs. rectal specimens.
In all female patients (OPD O&G and STD clinic), cervix or vagina sampling revealed 94.9% of the CT 
infected patients. Other sites are explained by sexual behaviour (rectum and pharynx). 
In male patients, urethral site sampling or urine revealed 85.9% of the CT infected patients. In men-
who-have-sex-with-men (MSM) the advice is to take rectal samples as well, to detect more patients.
The pharyngeal sampling site does not seem to contribute much to the detection of CT infected 
patients. 
Samples of 433 patients (256 female and 177 male) were collected sequentially and were used for CT 
serovar detection and typing. In 11 patients (2.6%) we found concurrent serovars in one sample site. In 
62 (34.1%) female (38 from the OPD O&G) and four (9.3%) male patients multiple sample site infections 
were found. A high percentage of women tested on the cervical/vaginal and rectal site were found positive 
on both sites (36.1%, 22 out of 61). In men, for serovar D/Da, E and G/Ga signifi cant differences were 
found in serovar distribution between urogenital and rectal specimens (D/Da: p= 0.0081, E: p=0.0012, 
and G/Ga: p=0.0033).
The prevalence of multiple serovar infections at different sites of the same individual is relative low. 
Therefore serovar analysis could be performed on one positive sample site. Signifi cant differences in 
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serovar distribution are found in rectal specimens of MSM with serovar G/Ga as the most prominent, 
suggesting tissue tropism. A same trend was found in women which, however, did not reach statistical 
signifi cance. 
Part II Serology
Continuously new commercially available species-specifi c (peptide-based) enzyme immunoassays 
(EIAs) are being developed for the detection of CT antibodies. Serological assays have been used to detect 
antichlamydial antibodies in the fertility workup, predicting tubal pathology. Their value for fertility 
evaluation remains an ongoing subject of debate. There is wide variation between various tests in the 
correlation of antichlamydial antibodies with both current CT infections and tubal pathology.
Therefore, in CHAPTER 4 we compare two new serological EIAs (pELISA (Medac) and Chlamydia-EIA 
(Biologische Analysensystem GmbH)) with microimmunofl uorescence (MIF) as a ‘gold standard’ to 
detect CT antibodies in pregnant women, subfertility patients, a control group of various gynaecological 
patients and CT positive patients. 
There were no signifi cant differences in seroprevalence rates, except for the group of CT-positive 
patients (p < 0.01). 
When we looked further in our subfertility group, we found that in 67% of women with patent tubes 
no CT IgG antibodies were detected by any of the assays, while in 27% of the women with tubal pathology 
no CT IgG antibodies were detected. A possible explanation could be that not in all patients with CT 
infections IgG antibodies are formed.
Test characteristics were calculated for pELISA and Chlamydia-EIA. The diagnostic accuracy of all 
assays showed relative poor performance in predicting tubal pathology. pELISA seems to be a good 
alternative to MIF. It has a high specifi city, is easier to perform and less expensive than MIF, and could 
therefore be used as a screenings test.
CHAPTER 5 focuses on CT heat shock protein 60 (cHSP60) antibodies in women without and with tubal 
pathology using a new commercially available assay.
cHSP60 assays are used in research setting in assessing serological responses to urogenital CT infection. 
Although comparison of the different ‘in-house’ assays is diffi cult owing to a lack of standardisation, 
there is a consensus among the users of these assays that the anti-cHSP60 responses in women increase 
with the severity of CT associated disease. A commercially produced assay that employs defi ned cHSP60 
epitopes should allow for the comparison of results obtained in different laboratories, as well as forward 
the use of cHSP60 as a diagnostic tool, if the assay proves to be relevant in predicting pathology or clinical 
outcome of a urogenital chlamydial infection. 











We evaluated a recently introduced commercially available cHSP60 serological assay (Medac, Wedel, 
Germany) and determined the anti-cHSP60 responses in three well defi ned groups of women (1. women 
without tubal pathology as assessed by either HSG or laparoscopy, 2. pregnant women (unknown tubal 
status, proved fertility), and 3. women with confi rmed tubal pathology). 
CT IgG positivity was previously determined to be 19% for group 1, 40% for group 2, and 64% for 
group 3, showing the expected clear difference in IgG seroprevalence between women with and with-
out procedure confi rmed tubal pathology, while an intermediate prevalence was observed in pregnant 
women. The same pattern but with lesser incidence was observed in the anti-cHSP60 responses being 
4.8%, 16%, and 27%, for groups 1–3, respectively (χ2 test for trend: χ2=3.1, p=0.079, group 1 vs. group 
3: p=0.096, OR 10.6). The incidences of anti-cHSP60 were increased in the CT IgG positive subgroups to 
25%, 35%, and 43%, for groups 1–3, respectively, while only 3.8% anti-cHSP60 titres were observed in 
the CT IgG negative subgroups, all in subgroup 2 (unknown tubal status, proved fertility). This indicates 
that the concordance between CT IgG and cHSP60 positivity is high, almost 90%; however, clearly a 
different subgroup of women is identifi ed by the cHSP60 assay since only 40% of the CT IgG positive 
women has a cHSP60 response (measurement of agreement: kappa 0.371). Finally, the median cHSP60 
titres increased from groups 1–3: 50, 100, and 200, respectively, suggesting an association between the 
level of cHSP60 response and tubal pathology. 
The results presented here, although obtained in small but well defi ned groups, look suggestively prom-
ising. Indeed, power calculations (alpha=0.5, beta=0.1) show that doubling (1.7 times) the size of the 
(sub)groups would result in signifi cant p values instead of clear trends. Therefore, further studies are 
needed in larger groups with different degrees of pathology due to CT infections to further determine the 
diagnostic, prognostic, and clinical relevance of this new assay. 
Part III Serovar
Currently, 19 different CT serovars and serovariants have been identifi ed by sero- and genotyping. The 
serovars can be divided into three serogroups: the B-group (serovars B, Ba, D, Da, E, L1, L2, L2a), the 
intermediate group (serovars F, G, Ga) and the C-group (serovars I, Ia, J, K, C, A, H, L3). The most 
prevalent CT strains worldwide are serovars D, E and F. They account for approximately 70% of the typed 
urogenital serovars. Conjunctivitis is mainly caused by serovars A-C. In urogenital infections serovars 
D-K are predominantly isolated. Serovars L1-L3 can be found in the inguinal lymph nodes.
Several studies have described inconclusive data about specifi c serovars and the clinical course of 
infection, the rate of upper genital tract progression, and the clearance-persistence rate. Information 
about the differences in serovar distribution could give information about the epidemiology of CT infec-
tions and might have clinical implications. A recent study about serovar distribution in the Netherlands 
showed no signifi cant serovar distribution shift over time, but geographical differences were observed. 
This could be the result of different ethnic composition.
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CHAPTER 6 relates to serovar distribution. The objective of this study is to determine the CT serovar 
distribution among different ethnic populations in the region The Hague in two well defi ned cohorts and 
to compare the results to previous obtained Dutch serovars distribution studies.
The overall distribution of serovars closely resembles that of found in other studies in the Netherlands. 
The predominance of the B-group serovars in most studies conducted in different geographic location 
and at different times suggests that these serovars have a biological advantage over the other serovars. 
Compared to the serovar distribution in the study of Spaargaren et al. we found signifi cant differences 
in serovar H and I/Ia. An association has been found between serovar Ia and (high-risk) black race. 
These racial differences in serovar distribution might be due to behavioural, geographical or biological 
factors. It has been suggested that one of the reasons could be that there is less mixing with partners 
from a different race (relatively closed populations). And geographic distribution could infl uence the 
distribution of serovar Ia. Also intrinsic biological differences among persons of different race or 
among chlamydial serovars could infl uence acquisition, transmission and duration of infection (host 
susceptibility or immune response). In the Netherlands higher prevalences of CT infections are found in 
Surinam and Netherlands Antilles (NA) patients. One might compare these high risk groups with high 
risk black patients in American studies. We compared serogroup distributions in different ethnic groups 
(Dutch Caucasian (DC), Surinam, NA and Turkish/Moroccan), but no signifi cant differences were found. 
Therefore, when ethnicity was taken into account no major differences were found.
Various demographic, clinical and behavioural parameters were analysed for a possible association with 
the infecting serogroup. For nearly all variables the serogroup distribution showed that serogroup B was 
most prevalent. 
The clinical course of infection does not seem to be infl uenced much by the infecting serovar. Further 
studies on the differences in clinical course should include analyses of host genetic factors. Host varia-
tion might play an important role in the development of clinical disease.
CHAPTER 7 presents the serologic responses of CT B-group serovars versus C- and I-groups.
Worldwide, serogroup B is the most prevalent followed by serogroup I. Clear differences have been 
observed in the duration of infection and growth kinetics between serovars from different serogroups 
in murine and cell culture models. Reasons for these observed differences are bacterial and host related, 
and are not well understood. 
We determined the differences in immunoglobulin (Ig) G responses between the three serogroups 
in a group of patients infected with different serovars. Serovars were assessed from 235 CT positive 
patients and quantitative IgG responses were determined. Analyses of variance were used to compare 
the IgG responses between the three serogroups. Of the serovars, 46% were B group (with serovar E the 
most prevalent: 35.3%), 39.6% were I group and 14.3% were C group. A highly signifi cant difference 











in serologic response was shown when comparing the mean IgG concentrations (AU/mL) of patients 
having serovars in the most prevalent serogroup compared to the other serogroups: B = 135, C = 46 and 
I = 60 (B vs. C and B vs. I, p< 0.001). 
This is the fi rst study to compare serologic IgG responses in urogenital CT infections based on sero-
group. The present study demonstrates that serovars of serogroup B induce higher serologic responses 
than serovars of serogroups C and I. The results of this study will be included in a much larger European 
Union Framework study to confi rm these results, to further enhance the power of the study, and enable 
multivariate analyses to obtain further insight into the immunopathogenesis of CT infections. This will 
enable risk profi ling of at-risk patients to prevent development of long-term complications.
Part IV General Discussion and Summary
In CHAPTER 8, the results of our two prospective-cohort studies are summarised and discussed in a 
broader spectrum. 
Which women are at what risk for upper genital tract infection and forthcoming sequelae of CT infec-
tions? We performed epidemiological studies to identify some base-line characteristics and hopefully 
future studies will contribute to the identifi cation of those at risk. Uterine instrumentation could lead to 
upper genital tract infection if an asymptomatic cervical infection is present, by ascending infection or by 
reactivation of viable microorganisms in the upper genital tract. Especially in a gynaecologic population, 
where these procedures are frequently performed, it is important to identify these women. 
Young age, complaints of contact bleeding, being of Surinam or Netherlands Antilles origin, and 
living in urban areas are important risk factors for CT infections. However, it turned out to be diffi cult to 
predict the increased risk of uterine instrumentation on the development of PID. Studies describing this 
are often not clear on the criteria of the diagnosis of PID or the causing agent. Whether screen-and-treat 
or antibiotic prophylaxis for all is the best policy remains therefore still subject of debate. Since it is not 
ethical to do a randomised-controlled trial on this subject, the decision which policy to follow will remain 
up to the physician. However, we advise that when intrauterine instrumentation is performed one should 
screen for CT infections in women in their fertile years (both by PCR and CAT). It is important to realise 
that pregnancy is not a guarantee for no infection. 
Nowadays, several assays can detect a CT and gonorrhoea in one sample. The role of other bacteria in 
the development of PID remains unclear.
In women, taking cervical swabs and urine analysis were complementary in the identifi cation of 
CT positive patients. In a gynaecologic population, in which a gynaecologic examination is performed 
in most patients, taking cervical swabs would give the most accurate information (with regard to the 
uterine instrumentation), without extra effort. However, for screening purposes urine analysis alone of 
self-taken vaginal swabs may be more acceptable. 
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There seems to be more and more evidence that Chlamydia antibody testing (CAT) can replace HSG in 
predicting tubal factor subfertility. Laparoscopy remains however the gold standard. But CAT can help to 
identify those patients in which a laparoscopy is indicated. Serological markers for persistent infection, 
i.e. CT IgA, cHSP60 and high-sensitivity C-reactive protein (hs-CRP), are more prevalent in women with 
tubal pathology. Especially the combination of CAT and hs-CRP needs further exploration, but seems 
promising in identifying women at high risk of tubal pathology. The combination of tests for humoral 
and cell-mediated immune response could help to improve the tubal factor subfertility prediction model .
Although we did fi nd some clear differences in serovar distribution as compared to previous Dutch 
published serovar studies, the clinical course of infection did not seem to be infl uenced much by the 
infecting serovar. Our ethnic groups were smaller than expected and therefore slightly underpowered. 
Since one comparison between DC and Netherlands Antilles patients was borderline signifi cant, larger 
studies might reveal clearer differences.
Further studies on the differences in clinical course should include analyses of host genetic factors. 
Host variation might play an important role in the development of clinical disease.
Serovars of serogroup B induce higher serologic responses than serovars of serogroups C and I. The 
results of this study will be included in a much larger European Union Framework study to confi rm these 
results, to further enhance the power of the study, and enable multivariate analyses to obtain further 
insight into the immunopathogenesis of CT infections. This will enable risk profi ling of at-risk patients 
to prevent development of long-term complications.
Finally, some recommendations and suggestions for future research are provided. 












Om epidemiologische risicofactoren voor Chlamydia trachomatis (CT) infecties te vinden en ter preventie 
van tubapathologie hebben wij twee prospectieve-cohort studies verricht. De resultaten worden in dit 
proefschrift gepresenteerd. De eerste studie werd beschreven tussen 2002 en 2004, en maakte gebruik 
van een goed gedefi nieerd cohort van patiënten die de polikliniek Obstetrie en Gynaecologie (O&G) 
bezochten in het centrum van Den Haag, en beschrijft de epidemiologische gegevens van patiënten met 
een CT infectie. 
In dezelfde populatie hebben we twee serologische tests voor het aantonen van CT antistoffen vergele-
ken, en hebben we de karakteristieken van een nieuw ontwikkelde test voor het aantonen van heat shock 
protein 60 (HSP60) antistoffen geëvalueerd en hun rol in het voorspellen van tubapathologie. 
In 2007 zijn we een tweede sequentiële studie gestart op dezelfde polikliniek Obstetrie en Gynaecolo-
gie en tevens op de dichtbij gelegen regionale GGD (SOA polikliniek), om zo de doelstellingen van onze 
studie af te ronden. 
CT infecties behoren tot de meest voorkomende seksueel overdraagbare aandoeningen in Nederland 
en ook wereldwijd. In Nederland lopen ca. 60.000 mensen jaarlijks een CT infectie op, waarvan 35.000 
vrouwen. Bij vrouwen verloopt 70% van de infecties asymptomatisch. Echter, infecties veroorzaakt door 
CT kunnen tot ernstige complicaties leiden, zoals pelvic infl ammatory disease (PID). Schade aan de tubae 
kan resulteren in (tuba factor) subfertiliteit en het krijgen van een extra-uteriene graviditeit. Bij zwan-
gere vrouwen kan de infectie leiden tot neonatale conjunctivitis en pneumonie. De hoogste prevalentie 
wordt gevonden bij jonge vrouwen, en zij lopen vooral risico op complicaties. Het is onbekend waarom 
sommige vrouwen een asymptomatische infectie doormaken en waarom er bij anderen sprake is van 
een symptomatisch hogere genitale infectie. Er wordt gesuggereerd dat verschillende serovars en/of 
gastheerfactoren betrokken kunnen zijn bij het klinisch beloop van de infectie, de mate van opstijgende 
infecties en het klaren of persisteren van de infectie. 
De behandeling van CT infecties is simpel en effectief, en kan late complicaties voorkomen als deze 
op tijd wordt gegeven. Met de ontwikkeling van technieken om CT aan te tonen in urinemonsters werden 
screeningsprogramma’s mogelijk en screeningsprogramma’s voor asymptomatische infecties worden 
nu op grote schaal toegepast. 
Intra-uteriene ingrepen, zoals het plaatsten van een intrauterine device (IUD), hysterosalpingogra-
fi e (HSG) en abortus curettage kunnen leiden tot een hogere genitale infectie als er sprake is van een 
asymptomatische cervicale infectie, door opstijgende infectie of door reactivatie van levensvatbare micro-
organismen in het hogere genitaal. Daarom is het belangrijk om in een populatie van obstetrische en 
gynaecologische patiënten risicofactoren voor een infectie te bepalen. 
Om de preventiestrategieën voor deze complicaties te optimaliseren, wilden we deze risicofactoren 
gebruiken voor onze obstetrische en gynaecologische populatie. Er is weinig bekend van de dynamiek van 
CT serovars en hun specifi eke rol in pathogeniciteit. Inzicht in de veranderingen van serovar distributie in 
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verschillende etnische groepen in het verloop van tijd, in relatie tot klinische gegevens, zou verschillen in 
de epidemiologie kunnen verklaren en zou klinische implicatie kunnen hebben. 
HOOFDSTUK 1 geeft een overzicht van de pathogenesis, het klinisch beloop en detectie methoden van 
CT infecties en beschrijft de doelstellingen van dit proefschrift. 
Deel I Klinische karakteristieken
In HOOFDSTUK 2 beschrijven we de prevalentie en risicofactoren van CT infecties in een algemene 
polikliniek Obstetrie en Gynaecologie in Nederland. 
Leeftijd was de meest belangrijke risicofactor in onze populatie (totale prevalentie van CT infecties 
4.5%, bij vrouwen jonger dan 20 jaar 15.8%). Een andere risicofactor was postcoïtaal bloedverlies. De 
signifi cante verschillen tussen vrouwen van verschillende etniciteit of tussen vrouwen die verschillende 
anticonceptiva gebruikten konden wij niet bevestigen. 
Twaalf (19.4%) patiënten met een CT infectie werden gevonden met alleen een positieve urinetest, 
en 15 (24.2%) met alleen de DNA-probe. In ons cohort vulden analyse van urine en van cervicale probes 
elkaar aan in het bepalen van de prevalentie van CT infectie bij vrouwen. 
Voor een richtlijn voor het preventieve gebruik van antibiotica bij intra-uteriene ingrepen is een 
kosten-baten analyse nodig om de mogelijkheden van leeftijdsgebonden screening en antibiotica pro-
fylaxe te beoordelen. 
In HOOFDSTUK 3 werpen we een nieuwe blik op de afnameplaatsen en we nemen tevens het serovar dat 
de infectie veroorzaakt mee in de overwegingen. 
De doelstellingen van deze studie waren het bepalen van de incidentie van dubbele infectie op serovar-
niveau, het bepalen van de incidentie van meerdere geïnfecteerde anatomische plaatsen CT detectie en 
serovar-niveau, en analyse van lokatie-specifi eke serovar-distributie, om de reactie op verschillen weef-
sels te identifi ceren, met speciale aandacht voor serovar G/Ga in urogenitale versus rectale afnamen.
Bij alle vrouwelijke patiënten (polikliniek O&G en SOA polikliniek), werd door middel van de cervicale 
en vaginale afnamen 94.4% van de met CT geïnfecteerde patiënten gedetecteerd. Andere locaties kunnen 
worden verklaard door seksueel gedrag (rectum en keel). 
Bij mannelijke patiënten openbaarde de urethrale afname of urine 85.9% van de met CT geïnfecteerde 
patiënten. Bij homo- of biseksuele mannen is het advies om ook rectale afnamen te doen om zo meer 
patiënten te detecteren. 
De keelafname lijkt niet veel bij te dragen aan het detecteren van CT geïnfecteerde patiënten. 
Afnamen van 433 patiënten (256 vrouw en 177 man) werden sequentieel verzameld en gebruikt voor CT 
serovar detectie en typering. Bij 11 patiënten (2.6%) vonden we dubbele serovars op één afname locatie. 











Bij 62 (34.1%) vrouwen (38 van de polikliniek O&G) en bij vier (9.3%) mannen werden CT infecties op 
meerdere afnamelocaties gevonden. Een hoog percentage van de vrouwen die zowel op de cervicale/
vaginale als rectale locatie was getest werd op beide locaties positief bevonden (36.1%, 22 van de 61). 
Bij mannen werd voor serovar D/Da, E, en G/Ga een signifi cant verschil gevonden tussen urogenitale en 
rectale afnamen (D/Da: p= 0.0081, E: p=0.0012, en G/Ga: p=0.0033).
De prevalentie van infecties met meerdere serovars op verschillende locaties in één individu is relatief 
laag. Daarom is serovar analyse slechts op één van de positieve locaties voldoende. Er werden signifi cante 
verschillen gevonden in serovar distributie van de rectale afnamen van homo- of biseksuele mannen met 
serovar G/Ga als meest prominente, wat verschil in gevoeligheid voor verschillende weefsels suggereert. 
Eenzelfde trend werd gevonden bij vrouwen, echter, dit haalde geen statistische signifi catie.
Deel II Serologie
Er worden continu nieuwe commercieel beschikbare species-specifi eke (peptide-gebaseerde) enzyme 
immunoassays (EIAs) ontwikkeld voor de detectie van CT antistoffen. Serologische testen zijn gebruikt 
voor het detecteren van antichlamydia antistoffen in het fertiliteitonderzoek, om tubapathologie te voor-
spellen. De waarde voor fertiliteitevaluatie blijft een onderwerp van discussie. Er bestaat een grote variatie 
tussen de verschillende testen in de correlatie tussen antichlamydia antistoffen en zowel een huidige CT 
infectie als tubapathologie. 
Daarom vergelijken wij in HOOFDSTUK 4 twee nieuwe serologische EIAs, pELISA (Medac) en Chlamy-
dia-EIA (Biologische Analysensystem GmbH)) met de microimmunofl uorescentie (MIF) als de gouden 
standaard, om CT antistoffen te detecteren bij zwangere vrouwen, subfertiele patiënten, een controle-
groep van patiënten met verschillende gynaecologische klachten en CT positieve patiënten. 
Er waren geen signifi cante verschillen in de seroprevalentiecijfers, behoudens voor de groep CT 
positieve patiënten (p<0.01). 
Wanneer we de subfertiliteitgroep verder bekeken, vonden we dat bij 67% van de vrouwen met door-
gankelijke tubae, door geen van de testen CT IgG antistoffen werden aangetoond, terwijl bij 27% van de 
vrouwen met tubapathologie, geen CT IgG antistoffen werden aangetoond. Een mogelijke verklaring zou 
kunnen zijn dat niet bij alle patiënten met een CT infectie IgG antistoffen worden aangemaakt. 
De testkarakteristieken voor de pELISA en Chlamydia-EIA werden berekend. De diagnostische nauw-
keurigheid van alle testen voor het voorspellen van tubapathologie was matig. De pELISA lijkt een goed 
alternatief voor de MIF. Het heeft een hoge specifi citeit, is makkelijker uit te voeren en goedkoper dan de 
MIF, en zou daarom gebruikt kunnen worden als een screeningstest. 
In HOOFDSTUK 5 richten we ons op CT heat shock protein 60 (cHSP60) antistoffen bij vrouwen met en 
zonder tubapathologie, gebruikmakend van een nieuwe commercieel beschikbare test. 
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cHSP60 testen worden in onderzoekssetting gebruikt bij het beoordelen van de serologische respons op 
een urogenitale CT infectie. Hoewel vergelijking tussen de verschillende ‘in-house’ testen moeilijk is door 
gebrek aan standaardisatie, is er wel consensus tussen de gebruikers van deze testen dat de anti-cHSP60 
respons bij vrouwen toeneemt met de ernst van de met CT geassocieerde ziekte. Met een commercieel 
geproduceerde test die gebruik maakt van gedefi nieerde cHSP60 epitopen zouden resultaten verkregen 
in verschillende laboratoria met elkaar vergeleken kunnen worden, en zou ook het gebruik van cHSP60 
als een diagnostisch hulpmiddel gestimuleerd kunnen worden, als de test relevant blijkt in het voorspel-
len van pathologie of klinische uitkomst van een urogenitale Chlamydia infectie. 
Wij evalueerden een recent geïntroduceerde commercieel beschikbare CHSP60 test (Medac, Wedel, 
Duitsland) en we bepaalden de anti-cHSP60 respons in drie goed gedefi nieerde groepen vrouwen (1. 
vrouwen zonder tubapathologie bij HSG of laparoscopie, 2. zwangere vrouwen (onbekende tuba status, 
bewezen fertiel), en 3. vrouwen met bewezen tubapathologie). 
De eerder bepaalde CT IgG positiviteit, 19% voor groep 1, 40% voor groep 2 en 64% voor groep 3, liet 
zoals verwacht een duidelijk verschil zien in IgG seroprevalentie tussen vrouwen met en zonder bewezen 
tuba pathologie, terwijl een intermediaire prevalentie werd opgemerkt bij zwangere vrouwen. Eenzelfde 
patroon, maar met een lagere incidentie, werd gevonden voor de anti-cHSP60 respons, te weten 4.8%, 
16%, en 27%, voor groep 1–3, respectievelijk (χ2 test voor trend: χ2=3.1, p=0.079, groep 1 vs. groep 3: 
p=0.096, OR 10.6). De incidentie van anti-cHSP60 was toegenomen in de CT IgG positieve subgroepen 
tot 25%, 35%, en 43%, voor groepen 1-3, respectievelijk, terwijl slechts 3.8% anti-CHSP60 titers werd 
gevonden in de CT IgG negatieve subgroepen, allen in subgroep 2 (onbekende tuba status, bewezen 
fertiel). Dit geeft aan dat de concordantie tussen CT IgG en cHSP60 positiviteit hoog is, bijna 90%; echter, 
er wordt duidelijk een andere subgroep van vrouwen geïdentifi ceerd door de cHSP60 test omdat slechts 
40% van de CT IgG positieve vrouwen een cHSP60 respons heeft (measurement of agreement: kappa 
0.371). Als laatste, de mediaan cHSP60 titer neemt toe van groep 1-3: 50, 100, en 200, respectievelijk, wat 
een associatie tussen het niveau van de cHSP60 respons en tubapathologie suggereert. 
De resultaten hier gepresenteerd, hoewel verkregen in kleine maar goed gedefi nieerde groepen, lijken 
veelbelovend. Powerberekeningen (alpha=0.5, beta=0.1) laten zien dat het verdubbelen (1.7 keer) van de 
grootte van de (sub)groepen zou resulteren in signifi cante p waarden in plaats van duidelijke trends. Ver-
dere studies zijn nodig in grotere groepen met verschillende ernst van tubapathologie door CT infecties 
om de diagnostische, prognostische en klinische relevantie van deze test vast te stellen. 
Deel III Serovar
Op dit moment zijn 19 verschillende CT serovars en serovarianten geïdentifi ceerd door middel van sero- 
en genotypering. De serovars kunnen in drie serogroepen onderverdeeld worden: de B-groep (serovars 
B, Ba, D, Da, E, L1, L2, L2a), the intermediaire groep (serovars F, G, Ga) en the C-groep (serovars I, Ia, 











J, K, C, A, H, L3). Wereldwijd komen serovars D, E en F het meest voor. Zij nemen ongeveer 70% van de 
getypeerde serovars voor hun rekening. Conjunctivitis wordt vooral veroorzaakt door de serovars A-C. 
Bij urogenitale infecties worden vooral serovars D-K geïsoleerd. De serovars L1-L3 worden vooral in de 
inguinale lymfeklieren gevonden. 
Er worden door verschillende studies niet overtuigende gegevens beschreven over specifi eke serovars 
en het klinisch beloop van de infectie, de mate van opstijgende infectie en het klaren of persisteren van 
de infectie. Verschillen in serovar-distributie zou informatie kunnen geven over de epidemiologie van CT 
infecties en kan klinische implicaties hebben. Een recente studie over de serovar-distributie in Nederland 
toonde geen distributie verschuiving in de tijd, maar er werden wel geografi sche verschillen gezien. Dit 
zou verklaard kunnen worden door verschillende etnische samenstelling. 
HOOFDSTUK 6 heeft betrekking op de serovar-distributie. De doelstelling van deze studie is om de CT 
serovar-distributie te bepalen in verschillende etnische populaties in de regio Den Haag, in twee goed 
gedefi nieerde cohorten, en om deze resultaten te vergelijken met eerder verrichtte Nederlandse serovar-
distributie studies. 
De totale serovar-distributie lijkt erg op wat ook in andere studies is gevonden in Nederland. Het over-
heersen van de B-groep serovars, zoals gevonden wordt in de meeste studies, op verschillende locaties en 
in verschillende tijdsperioden suggereert dat deze serovars een biologisch voordeel hebben ten opzichte 
van andere serovars. Vergeleken met de serovar-distributie studie van Spaargaren et al. vonden wij sig-
nifi cante verschillen voor serovar H en I/Ia. Er is een associatie gevonden tussen serovar Ia en (hoog 
risico) negroïde personen. Deze raciale verschillen zouden veroorzaakt kunnen worden door gedrags-, 
geografi sche- of biologische factoren. Er wordt gesuggereerd dat één van de redenen zou kunnen zijn 
dat er minder contact is met partners van een andere etniciteit (relatief gesloten gemeenschap). En de 
geografi sche verdeling zou de distributie van serovar Ia kunnen beïnvloeden. Ook intrinsieke biologi-
sche verschillen tussen personen van verschillende etniciteit of tussen verschillende serovars zouden 
het verkrijgen, de transmissie en de duur van de infectie (gastheer gevoeligheid of immuun respons) 
kunnen beïnvloeden. In Nederland worden hogere prevalenties van CT infecties gevonden bij patiënten 
van zowel Surinaamse als Antilliaanse herkomst. Deze groepen kunnen vergeleken worden met de hoog 
risico negroïde patiënten in Amerikaanse studies. Wij hebben serogroep-distributies vergeleken in 
verschillende etnische groepen (Dutch Caucasian (DC), Surinaams, Nederlandse Antillen (NA) en Turks/
Marokkaans), maar er werden geen signifi cante verschillen gevonden. Dus, wanneer er rekening werd 
gehouden met de etniciteit werden er geen grote verschillen gevonden. 
Om een mogelijke associatie met een serogroep aan te tonen werden verschillende demografi sche-, kli-
nische- en gedrags-parameters geanalyseerd. Voor vrijwel alle variabelen gold dat serogroep B het meest 
voorkomend was in de serogroep-distributie. 
Het klinisch beloop van de infectie lijkt niet erg beïnvloed te worden door het infecterende serovar. 
Nieuwe studies over verschillen in het klinisch beloop zouden analyse van gastheer-genetische factoren 
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mee moeten nemen. Gastheer-variatie zou een belangrijke rol kunnen spelen in de ontwikkeling van 
klinische ziekte. 
In HOOFDSTUK 7 wordt de serologische respons weergegeven van de CT B-groep serovars versus de 
C- en I-groep. 
Wereldwijd zijn de B-groep serovars het meest voorkomend, gevolgd door serogroep I. In muis en cel cul-
tuur onderzoek worden duidelijke verschillen gevonden tussen serovars van verschillende serogroepen 
in de duur van de infectie en groei kinetiek. Redenen voor deze verschillen zijn bacterieel en gastheer 
gerelateerd, maar worden nog niet goed begrepen. 
Wij hebben de verschillen in immunoglobuline (Ig) G respons bepaald tussen de drie serogroepen bij 
patiënten die met verschillende serovars geïnfecteerd waren. Bij 235 CT positieve patiënten werden sero-
vars getypeerd en en werd de kwantitatieve IgG respons bepaald. Variantie-analyse werd toegepast om 
de IgG responses tussen de drie serogroepen te vergelijken. Van alle serovars kwam 46% uit de B-groep 
(met serovar E als meest voorkomende:35.3%), 39.6% uit de I-groep en 14.3% uit de C-groep. Er werd 
een zeer signifi cant verschil in de serologische respons gezien wanneer de gemiddelde IgG concentraties 
(AU/ml) van patiënten met serovars uit de meest voorkomende serogroep werden vergeleken met andere 
serogroepen: B = 135, C = 46 en I = 60 (B vs. C en B vs. I, p< 0.001). 
Dit is de eerste studie die een vergelijking maakt van serologische IgG respons bij urogenitale CT 
infecties op basis van serogroepen. Deze studie laat zien dat de serovars van de B-groep een sterkere 
serologische respons induceren dan de serovars van de C- en I-groep. Het resultaat van deze studie zal 
geïncludeerd worden in een grotere studie van de Europese Unie om deze resultaten te bevestigen, om 
de power van de studie verder te verhogen, en om multivariate analyse mogelijk te maken, om zo meer 
inzicht te verkrijgen in de immunopathogenese van CT infecties. Dit zal risicoprofi lering mogelijk maken 
van risico patiënten om zo langetermijn-complicaties te voorkomen. 
Deel IV Algemene Discussie en Samenvatting
In HOOFDSTUK 8 worden de resultaten van onze twee prospectieve-cohort studies samengevat en en 
bediscussieerd in een breder spectrum.
Welke vrouwen lopen welk risico op opstijgende infectie en de restverschijnselen die daardoor ontstaan? 
Wij hebben epidemiologische studies verricht om een aantal basiskarakteristieken te identifi ceren en 
hopelijk kunnen toekomstige studies bijdragen aan de identifi catie van risicopatiënten. Intra-uteriene 
ingrepen kunnen leiden tot een hogere genitale infectie als er sprake is van een asymptomatische cervicale 
infectie, door opstijgende infectie of door reactivatie van levensvatbare micro-organismen in het hogere 











genitaal. Vooral in een gynaecologische populatie, waar deze ingrepen frequent worden uitgevoerd, is het 
van belang deze vrouwen te identifi ceren.
Jonge leeftijd, klachten van postcoitaal bloedverlies, Surinaamse of Antilliaanse etniciteit en het wonen 
in stedelijke gebieden zijn belangrijke risicofactoren voor CT infecties. Het bleek echter moeilijk om 
het toegenomen risico door intra-uteriene ingrepen op het ontwikkelen van een PID te voorspellen. In 
studies waarin dit onderwerp beschreven wordt zijn de criteria vaak niet duidelijk waarop de diagnose 
PID is gesteld, of over het micro-organisme dat de infectie veroorzaakt. Of screen-and-treat of antibiotica 
profylaxe de beste strategie is blijft nog onderwerp van discussie. Omdat het niet ethisch verantwoord 
is hier een randomized-controlled trial over te doen, zal de beslissing welke strategie te volgen bepaald 
worden door de behandelend arts. Wij adviseren echter, om bij intra-uteriene ingrepen te screenen op CT 
infecties bij vrouwen in de vruchtbare leeftijd (middels PCR en CAT).Het is belangrijk om te realiseren dat 
zwangerschap geen garantie is voor de afwezigheid van een infectie.
Tegenwoordig kunnen door verschillende testen zowel CT als gonorroe in één afname bepaald wor-
den. De rol van andere bacteriën bij de ontwikkeling van een PID blijft onduidelijk.
Bij vrouwen zijn cervix afname en urine-analyse aanvullend bij het identifi ceren van CT positieve 
patiënten. In een gynaecologische populatie, waar gynaecologisch onderzoek bij de meeste patiënten 
wordt verricht, geeft het afnemen van cervix kweken de meest nauwkeurige informatie (met betrekking 
tot intra-uteriene ingrepen), zonder extra moeite. Echter, voor screeningsdoeleinden zijn urine-analyse 
of zelf-afgenomen vaginale kweken meer acceptabel.
Er komt steeds meer bewijs dat chlamydia antibody testing (CAT) het HSG kan vervangen bij het voor-
spellen van tubapathologie. Laparoscopie blijft echter de gouden standaard. Maar CAT kan helpen bij 
het identifi ceren van die patiënten bij wie een laparoscopie geïndiceerd is. Serologische markers voor 
een persisterende infectie, zoals CT IgA, cHSP60 en high-sensitivity C-reactive protein (hs-CPR), zijn 
vaker aanwezig bij vrouwen met tubapathologie. Vooral de combinatie van CAT en hs-CRP dient verder 
onderzocht te worden, en lijkt veelbelovend bij het identifi ceren van vrouwen met een hoog risico op 
tubapathologie. De combinatie van testen voor humorale en cel-gemedieerde immuun respons zouden 
kunnen helpen bij het verbeteren van het tuba factor subfertiliteit predictiemodel.
Alhoewel wij enkele duidelijke verschillen vonden in serovar-distributie in vergelijking met andere Neder-
landse studies, lijkt het klinisch beloop van de infectie niet erg beïnvloed te worden door het serovar dat 
de infectie veroorzaakt. Onze etnische groepen zijn wat kleiner dan verwacht en daardoor underpowered. 
Omdat één vergelijking tussen DC en Antilliaanse patiënten bijna signifi cant was, zouden grotere studies 
duidelijker verschillen kunnen laten zien. Nieuwe studies over verschillen in het klinisch beloop zouden 
analyse van gastheer-genetische factoren mee moeten nemen. Gastheer-variatie zou een belangrijke rol 
kunnen spelen in de ontwikkeling van klinische ziekte.
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De serovars van de B-groep induceren een sterkere serologische respons dan de serovars van de C- en 
I-groep. Het resultaat van deze studie zal geïncludeerd worden in een grotere studie van de Europese Unie 
om deze resultaten te bevestigen, om de power van de studie verder te verhogen, en om multivariate ana-
lyse mogelijk te maken, om zo meer inzicht te verkrijgen in de immunopathogenese van CT infecties. Dit 
zal risicoprofi lering mogelijk maken van risicopatiënten om zo langetermijn-complicaties te voorkomen. 
Als laatste worden nog aanbevelingen en suggesties voor verder onderzoek gedaan.
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PID pelvic infl ammatory disease
TFI tubal factor infertility
STI sexual transmitted infection




CAT Chlamydia antibody testing
HSP heat shock protein
hs-CRP high-sensitivity C-reactive protein
EIA enzyme immunoassay
DFA  direct fl uorescent antibody assay
NAAT nucleic acid amplifi cation test
POC point of care (rapid test)
MIF microimmunofl uorescence
TMA template mediated amplifi cation
PCR polymerase chain reaction
LCR  ligase chain reaction
FVU fi rst-void urine
DC Dutch Caucasian
NA Netherlands Antilles
RFLP restriction fragment length polymorphism
MLST  Multi Locus Sequence Typing
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